A novel alpha-synuclein K58N missense variant in a patient with Parkinson's disease

2

3	Mohammed Al-Azzani ^{1†} , Sandrina Weber ^{2†} , Nagendran Ramalingam ³ , Maria Ramón ¹ , Liana
4	Shvachiy ¹ , Gonçalo Mestre ¹ , Michael Zech ^{4,5,6} , Kevin Sicking ^{7,8} , Alain Ibáñez de Opakua ⁹ ,
5	Vidyashree Jayanthi ³ , Leslie Amaral ^{1,10} , Aishwarya Agarwal ¹¹ , Aswathy Chandran ¹¹ , Susana R.
6	Chaves ¹⁰ , Juliane Winkelmann ^{4,5,12,13} , Claudia Trenkwalder ^{14,15} , Maike Schwager ¹⁶ , Silke Pauli ¹⁶ ,
7	Ulf Dettmer ³ , Claudio O. Fernández ¹⁷ , Janin Lautenschläger ¹¹ , Markus Zweckstetter ^{9,18} , Ruben
8	Fernandez Busnadiego ^{7,8,19,20} , Brit Mollenhauer ^{2,15*} , and Tiago Fleming Outeiro ^{1,9,21,22*}
9	
10	¹ University Medical Center Göttingen, Department of Experimental Neurodegeneration, Center
11	for Biostructural Imaging of Neurodegeneration, Göttingen, Germany.
12	² Department of Neurology, University Medical Center Goettingen, Goettingen, Germany.
13	³ Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and
14	Harvard Medical School, Boston, Massachusetts, United State.
15	⁴ Institute of Neurogenomics, Helmholtz Zentrum München, German Research Center for
16	Environmental Health, Neuherberg, Germany.
17	⁵ Institute of Human Genetics, TUM School of Medicine and Health, Technical University of
18	Munich, Munich, Germany.
19	⁶ Institute for Advanced Study, Technical University of Munich, Garching, Germany.
20	⁷ University Medical Center Göttingen, Institute for Neuropathology, Göttingen, 37077 Germany.
21	⁸ Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase,
22	MD, USA.
23	⁹ German Center for Neurodegenerative Diseases (DZNE), Von-Siebold-Str. 3a, 37075 Göttingen,
24	Germany.

- ¹⁰ CBMA Centre of Molecular and Environmental Biology, School of Sciences, University of
- 26 Minho, 4710-057 Braga, Portugal.
- ¹¹ Cambridge Institute for Medical Research, University of Cambridge, Cambridge Biomedical
- 28 Campus, The Keith Peters Building, Hills Road, Cambridge, CB2 0XY, UK.
- ¹²Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
- ¹³German Center for Mental Health (DZPG), partner site Munich-Augsburg, Munich-Augsburg,
- 31 Germany.
- ¹⁴Department of Neurosurgery, University Medical Centre Goettingen, Goettingen, Germany.
- ¹⁵Paracelsus-Elena-Klinik, Kassel, Germany.
- ³⁴ ¹⁶Institute of Human Genetics, University Medical Center Göttingen, Göttingen, Germany.
- ¹⁷ Max Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario
- 36 (MPLbioR, UNR-MPINAT), Partner Laboratory of the Max Planck Institute for Multidisciplinary
- 37 Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, Universidad Nacional de
- 38 Rosario, Rosario, Argentina.
- ¹⁸Department for NMR-based Structural Biology, Max Planck Institute for Multidisciplinary
- 40 Sciences, Am Faßberg 11, 37077, Göttingen, Germany.
- 41 ¹⁹Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of
- 42 Excitable Cells" (MBExC), University of Göttingen, Göttingen, 37077, Germany
- ⁴³ ²⁰ Faculty of Physics, University of Göttingen, Göttingen, 37077, Germany
- 44 ²¹Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle
- 45 University, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.
- ²² Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany.
- 47 **†Co-first authors**
- 48
- 49 ***Co-corresponding authors:**

50	Prof. Dr. Tiago Fleming Outeiro						
51	Email: tiago.outeiro@med.uni-goettingen.de						
52							
53	Prof. Dr. Brit Mollenhauer						
54	Email: brit.mollenhauer@med.uni-goettingen.de						
55							
56	Running title: A novel alpha-synuclein K58N variant in PD						
57							
58	Keywords: Alpha-synuclein; Parkinson's disease; genetics; neurodegeneration; protein	n					
59	aggregation						
60							
61							
62							
63							
64							
65							
66							
67							
68							
69							
70							
71							
72							

73 Abstract

Mutations and multiplications in the SNCA gene, encoding alpha-synuclein (aSyn), are associated with familial forms of Parkinson's disease (PD). We report the identification of a novel SNCA missense mutation (NM 000345.4, cDNA 174G>C; protein K58N) in a PD patient using whole exome sequencing, and describe comprehensive molecular and cellular analysis of the effects of this novel mutation. The patient exhibited typical sporadic PD with early onset and a benign disease course. Biophysical studies revealed that the K58N substitution causes local structural effects, disrupts binding to membranes, and enhances aSyn in vitro aggregation. K58N aSyn produces fewer inclusions per cell, and fails to undergo condensate formation. The mutation increases the cytoplasmic distribution of the protein, and has minimal effect on the dynamic reversibility of serine-129 phosphorylation. In total, the identification of this novel mutation advances our understanding of aSyn biology and pathobiology.

98 Introduction

Parkinson's disease (PD) is an age-associated neurodegenerative disorder that classically 99 manifest clinically by a triad of cardinal motor symptoms of tremor, rigidity, and bradykinesia, as 100 well as non-motor symptoms like depression, autonomic dysfunction and dementia (1, 2). 101 Neuropathologically, PD is marked by the progressive degeneration of dopaminergic neurons in 102 in the substantia nigra and the presence of Lewy bodies (LBs), which are intraneuronal inclusions 103 predominantly composed of aggregated alpha-synuclein (aSyn) (3-6). In addition to PD, 104 misfolding and aggregation of aSyn into protein inclusions is present in other neurodegenerative 105 disorders grouped together as synucleinopathies, such as dementia with Lewy bodies (DLB) and 106 multiple system atrophy (MSA). Importantly, increasing evidence points to different structural 107 organization of aSyn fibrils within inclusions that varies according to the synucleinopathy (7-9). 108

aSyn, an intrinsically disordered protein, has been a significant focus of neuroscience research not only due to its central role in PD and related synucleinopathies, but also because of its abundance and function in the nervous system. aSyn is primarily concentrated in the presynaptic terminals of neurons, but is also present in other cellular compartments including the nucleus, and is thought to interact with membranes adopting helical conformations and tetrameric structures (*10, 11*). Nevertheless, the precise physiological functions of aSyn are still poorly understood, especially in what concerns its function in non-neuronal cells.

In pathological conditions, aSyn is thought to misfold and accumulate, forming pathological aggregates that disrupt cellular homeostasis, in a process that may ultimately cause neuronal cell death. Dopaminergic neurons in the substantia nigra seem particularly vulnerable to the toxic damage of pathological aSyn aggregates, although the underlying mechanisms remain unclear. While aSyn aggregation has been typically considered the driver of neurodegeneration, other theories suggest that the loss of functional monomeric aSyn due to aggregation, also known as

synucleinopenia, may lead to disease progression (12, 13). In reality, a combination of

123 proteinopathy and proteinopenia are likely to contribute to disease.

Missense mutations in SNCA, the gene that encodes aSyn, are linked to familial forms of PD, 124 suggesting that determining the molecular effects of such mutations may prove important for our 125 understanding of the pathological underpinnings of the disease. In fact, since the discovery of the 126 first SNCA mutation encoding for the A53T substitution (3), the field of PD genetics has enabled 127 the identification of several other SNCA mutations as well as mutations in several other genes in 128 PD (14, 15). Several variants of aSyn have been linked to familial forms of PD and include, for 129 130 example, G14R, V15A, A30G, A30P, E46K, H50Q, G51D, A53T, A53E, A53V, T72M, highlighting the importance of aSyn in PD (3, 6, 16-24). However, mutations in the SNCA gene 131 are extremely rare and account for only 0.1-0.2% of cases (14). In addition, duplications or 132 triplications of the chromosomal region containing the SNCA gene are also associated with 133 familial forms of PD (25). These multiplications are consistent with a dose-dependent effect, as 134 SNCA triplications cause a fully penetrant and severe phenotype with early onset and common 135 non-motor symptoms like depression, psychosis and cognitive decline (26, 27), while duplications 136 on the other hand, are associated with a more variable clinical presentation, and more often 137 present with Dementia with Lewy bodies rather than PD (26). Missense mutations are generally 138 rarer than duplications (15, 28), and are associated with a broad clinical spectrum that ranges from 139 presentations resembling idiopathic PD, to more complex phenotypes, with atypical signs (29), 140 141 resembling atypical PD or other neurodegenerative disorders. Consistently, our group has recently described the novel variant G14R, that is associated with an atypical, rapidly progressive 142 phenotype and widespread neuronal loss in combination with frontotemporal lobar degeneration-143 144 associated aSyn pathology (24). To date, only a limited number of missense variants have been 145 reported, including variants with unresolved pathogenic relevance and variants that have yet to undergo independent replication (21, 30, 31). In addition to the clinical heterogeneity, the 146

147	identification of SNCA missense variants is hampered by the fact that some variants demonstrate
148	incomplete penetrance (16, 32), resulting in negative family histories. Consequently, validating
149	known variants and identifying novel ones are crucial for improving diagnostic accuracy and for
150	informing genetic counseling. Furthermore, SNCA missense variants are of tremendous interest
151	for researchers because of their potential to expand our understanding of the molecular
152	mechanisms underlying aSyn aggregation as well as pathological and physiological properties,
153	including phosphorylation at S129 (pS129) (33, 34). For instance, different missense variants
154	have been associated with increased or decreased pathologic properties like aggregation and
155	phosphorylation status (24, 35-37). Thus, investigating these variants offers an invaluable
156	opportunity to advance our knowledge of the physiological and pathophysiological roles of aSyn.

In this study, we identified a novel heterozygous missense mutation in a case of familialPD and provide a detailed description of the clinical phenotype and molecular effects.

159

160 **Results**

161 Clinical presentation

The index patient is a male Caucasian that presented initial motor symptoms approximately in his 162 late 30s, with left-sided rest tremor, reduced arm swing and mild bradykinesia on the left side. He 163 was diagnosed with early-onset PD (EOPD) in his early 40s. A dopamine transporter Imaging 164 showed asymmetrical decrease consistent with PD, and no signs indicative of atypical PD or other 165 neurologic disorders were found on clinical examination. After a good initial response to 166 dopamine agonists and dopamine, the patient developed motor-fluctuations with end-of-dose 167 wearing-off, trunk dyskinesias in the on-phase and freezing-of-gait. Marked dystonia was present 168 in the left arm and leg. 13 years after PD diagnosis, he was evaluated for deep brain stimulation 169 170 (DBS). At that time, non-motor symptoms included excessive daytime sleepiness, fatigue and depression. Comprehensive neuropsychologic assessment found no signs of cognitive dysfunction 171

172 and a repeated MRI showed no pathologic findings or signs consistent with atypical PD. Presurgical levodopa-response as evaluated by levodopa-challenge test was highly effective, with 173 an improvement of UPDRS-III of 78%. The patient received bilateral DBS of the subthalamic 174 nucleus that reduced the severity of motor fluctuations, freezing, and tremor. Post-surgical follow-175 up 3 years after DBS implantation showed sustained good effects on motor-symptoms, overall 176 good cognition with MMSE 30/30 but re-emergence of moderate motor-fluctuations. The family 177 history was positive, and both a parent and a grandparent were affected by PD. Both relatives 178 were already deceased but were reported to have had no atypical symptoms and no dementia. 179

180

181 Whole-exome sequencing identifies aSynp.K58N point mutation

The patient was selected for genetic testing by whole-exome sequencing (WES) due to the early onset of PD and the positive family history. WES identified a novel heterozygous missense variant in *SNCA* (NM_000345.4, cDNA 174G>C; protein K58N) (Fig. S1 A and B). The variant was not annotated in the genomic databases gnomAD and the PD Variant Browser. It causes a missense substitution in a phylogenetically highly conserved region (Fig. S1 C) and is predicted as deleterious by several in-silico prediction algorithms (CADD:31, PolyPhen-2: 0.994, PrimateAI: 0.8337, REVEL: 0.653).

189

K58N mutation causes a reduction in α-helical content, impairing its interaction with liposomes

In order to study the impact of K58N mutation on the structural and membrane-binding properties characteristics of aSyn, we employed NMR spectroscopy and circular dichroism (CD) using recombinantly prepared monomeric WT and K58N aSyn. The two-dimensional NMR ¹H/¹⁵Ncorrelation spectra for both proteins revealed minimal signal spread as expected for IDPs (Fig. 1 A). Spectral comparison showed that the majority of the cross peaks for both variants aligned

together except for those linked to residues located around the mutation site (Fig. 1 B-D). The
disturbances in the NMR signal shifts and intensity were restricted to the vicinity of the K58N
mutation as shown in (Fig. 1 B-D).

To gain insight into how this could affect the local conformation of K58N aSyn, we calculated the 200 secondary structure from NMR chemical shifts around the mutation area. Interestingly, we 201 observed a reduction in the amount of α -helical content with the K58N mutation in that region 202 (Fig. 1 E). Furthermore, MD simulations of the aSyn peptide G51-N65 either containing the WT 203 lysine or an asparagine at position 58 reproduced the difference observed in the experimental 204 NMR data of the full-length protein showing a decrease in α -helix content for the mutant, albeit 205 with different total values (Fig. 1 F). The findings from both experimental and simulation 206 demonstrate that K58N mutation impact the helical propensity surrounding the mutation site (Fig. 207 1 E and G). 208

aSyn is known to form α -helical structures upon binding to membranes. Therefore, we 209 investigated the effect of K58N mutation on its interactions with membranes by incubating both 210 WT and K58N aSyn with increasing amounts of liposomes and utilizing CD, a well-established 211 technique for monitoring the transition of aSyn into membrane-bound *a*-helical conformations 212 (38-40). The exposure to liposomes resulted in a shift from random coil into α -helical structure 213 for both variants (Fig. 1 H and I). However, analysis of the change in the ellipticity at 222 nm 214 revealed that K58N mutation exhibited a lower tendency to adopt α -helical conformations when 215 exposed to liposomes reflecting a reduction of the binding to liposomes (Fig. 1 J). In summary, 216 the NMR data shows that the α -helical content is reduced by the mutation in the monomeric state, 217 which may explain the decreased liposome binding, as the liposome-bound aSyn tends to form 218 219 alpha-helix in that region.

220

221 Effect of the K58N mutation on aSyn aggregation in vitro

222 A central pathological hallmark in PD and other synucleinopathies is the accumulation of aSyn into insoluble aggregates. Therefore, we investigated the aggregation propensity of the K58N 223 variant in comparison to WT aSyn. To check this, we initially assessed the aggregation propensity 224 of K58N variant employing various computational prediction algorithms (41-43). These 225 algorithms showed increase in β -strand content, and a higher tendency in the aggregation 226 properties for K58N aSyn (Fig. S2). Experimentally, recombinant WT and K58N aSyn were 227 incubated under shaking conditions to monitor the fibrillization kinetics of both proteins, 228 following an in vitro ThT-based aggregation assay protocol. Interestingly, the K58N showed a 229 230 higher ThT aggregation profile compared with WT aSyn (Fig. 2 A-B and D). Furthermore, the K58N variant demonstrated different aggregation kinetics, with a shorter $t_{1/2}$ suggesting a faster 231 rate of fibril formation (Fig. 2 C). These findings prompted us to perform detailed cryo-EM 232 analysis of the morphological, organizational, and structural features of fibrils prepared by both 233 As previously reported (24), WT a-Syn fibrils adopted two similarly populated variants. 234 conformations, consisting of one (1PF) or two protofilaments (2PF) respectively (Fig. 3A, C; Fig. 235 S3). 3D reconstruction was only successful for 2PF fibrils, resulting in a structure with 2.7 Å 236 global resolution (Fig. 3 E; Fig. S3; Fig. S4) that enabled building of an atomic model. This 237 model displays a double-arrow fold previously observed in other studies, such as "polymorph 2A" 238 reported by (44). Similar to that structure, our model features a salt bridge between lysine 45 239 (K45) and glutamic acid 57 (E57) that stabilizes the inter-protofilament interface (Fig. 3G, H). 240 241 The protofilament fold itself is nearly identical to those described as "polymorph L2A and L2B" by (45) and "protofilament fold B" by (46). However, in these cases, the inter-protofilament 242 interactions differ. 243

In contrast, K58N adopted almost exclusively 2PF conformations (Fig. 3B, D; Fig. S5). An atomic model based on the 3D reconstruction of these fibrils at 3.7 Å global resolution revealed a similar protofilament fold as in WT fibrils (Fig. 3F, I, J, Fig. S4). However, K58N fibrils present

a higher twist (-1.29 degrees vs -0.81 degrees in WT fibrils), and a slightly shifted protofilament interface, possibly due to the proximity of the mutation site (K58) to the interface stabilizing residue (E57). Additionally, no density for residues 14-25 was visible at the periphery of mutant fibrils (Fig. 3G-J). Altogether, these data indicate that the K58N mutation displaces the conformational equilibrium of a-Syn fibrils towards a 2PF structure reminiscent of that observed for WT.

253

K58N mutation alters aSyn inclusion number and size in a cellular model

255 After studying the impact of K58N mutation on aggregation of aSyn in vitro, we next explored whether a similar aggregation tendency can be observed under cellular environment. To this end, 256 we employed the SynT/Sph1 model, a well-recognized methodology that has been used regularly 257 to study aSyn aggregation in cells (47). Human neuroglioma cells (H4) were first co-transfected 258 with WT or K58N SynT variants and Sph1 followed by immunostaining to assess inclusion 259 formation 48 hours post-transfection. Interestingly, cells expressing K58N SynT mutation 260 exhibited a significant decrease in the number of aSyn inclusions in comparison to cells 261 expressing WT aSyn (Fig. 4 A and B). The inclusions observed in K58N transfected cells were 262 smaller in size (Fig. 4 C). Moreover, a significant increase in the percentage of cells without 263 inclusions was observed in cells expressing K58N version (Fig. S6). 264

265

K58N aSyn shows decreased phase separation

We further explored the impact of this novel mutation on aSyn phase separation properties, a critical factor that is thought to play a role in its functional and pathological behavior. We find that K58N aSyn undergoes only minimal droplet formation compared to aSyn wild-type (WT) when tested under otherwise same conditions (Fig. 5 A). This is recapitulated at a quantitative

scale, testing aSynK58N phase separation using turbidity measurements in the presence of Ca^{2+}

and varying PEG concentrations (Fig. 5 B).

We next expressed aSyn YFP with VAMP2 in HeLa cells, where VAMP2 induces aSyn phase
separation as previously shown (*48*). Here, WT aSyn YFP shows condensate formation, however
K58N aSyn YFP fails to form condensates exhibiting a homogenous cytosolic distribution (Fig. 5
C). Quantitative evaluation confirms the absence of condensate formation for the K58N aSyn
variant (Fig. 5 D).

278

279 Effects of the K58N mutation on aSyn S129 phosphorylation

There is increasing evidence that serine-129 phosphorylation (pS129) of aSyn is not only 280 associated with pathology but also influences the physiological function of aSyn (34). Therefore, 281 we investigated whether the K58N mutation alters the pS129 status. To address this, we employed 282 lentiviral vectors to express either human WT or K58N variants in primary aSyn knockout 283 (SNCA-/-) rat cortical cultures (Fig. 6 A). We first checked the levels of pS129 in the absence of 284 neuronal stimulation. Compared to WT aSyn, K58N mutant exhibited a significant reduction in 285 basal pS129 (Fig. 6 B). Recent studies have shown that familial PD-associated aSyn mutants with 286 reduced membrane (M) localization is often associated with lower basal pS129 levels (34). Given 287 the observed decrease in pS129 levels observed here for K58N mutant, we hypothesized that this 288 decrease could be attributed to increased solubility or, in other words, decreased membrane 289 association (M). In line with this, we observed that the K58N mutation was enriched in the 290 cytosolic fraction (C) (GAPDH fraction, ~ 62%) (Fig. 6 C and D), supporting the idea that 291 reduced membrane association contributes to lower pS129 levels. 292

Phosphorylation of S129 also has been recently reported to be an activity dependent, dynamic physiological process. According to these studies, pS129 is elevated following neuronal stimulation and then returns to baseline once the stimulus dampens or when inhibited in a

296 dynamic reversible process (34). Importantly, rodent neuron cultures expressing PD-associated A30P and E46K aSyn mutants showed impaired dynamic reversibility of pS129 (49). To assess 297 the effect of the K58N PD-associated mutation on the dynamic reversibility of pS129, we exposed 298 WT or K58N aSyn transduced rat SNCA-/- cortical neurons to neuronal stimulation, inhibition, 299 or a combination of stimulation followed by inhibition (Fig. 6 E). At DIV 17-21, cortical cultures 300 were stimulated with picrotoxin (PTX), a GABA_A receptor antagonist, to stimulate neuronal 301 activity and inhibited by the sodium channel blocker, tetrodotoxin (TTX). Consistent with our 302 previous observations, the exposure of neurons to PTX for 2h and 4h significantly increased 303 304 pS129 levels in WT neurons, while neuronal inhibition through TTX decreased the basal levels by approximately 30%. The TTX inhibition 2h post-PTX stimulation effectively reversed activity-305 dependent pS129 elevation (Fig. 6 F). K58N neurons followed a comparable pattern of activity-306 dependent pS129 response (Fig. 6 G). Interestingly, however, PTX treatment for 4h induced a 307 more pronounced increase in pS129 in K58N aSyn neurons compared to that of WT, relative to 308 basal levels (Fig. 6 H). Then, we compared the 4h PTX stimulation combined with TTX 309 inhibition introduced midway to 2h or 4h PTX stimulation in order to evaluate the dynamic 310 reversibility of pS129. The percentage of irreversible pS129 levels in PTX/TTX-treated neurons 311 was comparable between K58N and WT aSyn relative to PTX stimulation for 2h (Fig. 6 K). 312 However, after 4h of PTX stimulation, a lower proportion of irreversible in K58N neurons 313 compared to WT aSyn expressing neurons (Fig. 6 L). We assessed the sensitivity of K58N 314 transduced neurons to TTX inhibition under unstimulated conditions and found no significant 315 differences between K58N and WT neurons (Fig. 6 I). In conclusion, our findings indicate that 316 activity-dependent pS129 is altered in the disease-associated K58N aSyn mutant, with a 317 pronounced effect in response to prolonged neuronal activity. 318

319

320 **K58N** is more cytosolic without changing cytotoxicity in yeast cells

To investigate how the K58N aSyn mutation affects cellular distribution and cytotoxicity, we used the well-established budding yeast model to associate subcellular localization with toxicity (*50*). In our results we observed that the K58N aSyn is predominantly localized to the cytoplasm in yeast cells, in contrast to WT aSyn, which tended to form cytoplasmic inclusions (Fig. 7 A). Despite the different subcellular localization, the K58N and WT aSyn presented identical toxicities (Fig. 7 B).

327

328 Discussion

Here, we report the discovery of missense mutation K58N in the SNCA gene and provide a 329 detailed description of the associated clinical phenotype and molecular effects of this novel 330 mutation. The variant was identified through WES in a patient with EOPD and a positive family 331 history, both of which raised the suspicion of an underlying genetic cause. Although both affected 332 relatives were already deceased, and no DNA was available to confirm the mutation, the 333 pathogenic relevance of K58N is supported by (1) the absence of K58N in genomic databases, (2)334 the disruption of a highly conserved amino acid residue, (3) the prediction of a pathogenic effect 335 by different in-silico tools, and most importantly, (4) the results of the molecular characterization, 336 that are discusses in detail further down. According to ACME (American College of Medical 337 Genetics) guidelines (51), the variant is classified as *likely pathogenic*. 338

The clinical presentation and progression were similar to idiopathic PD, with a good and sustained levodopa-response and the lack of motor- and non-motor-symptoms indicating atypical PD. Both father and grandfather were also diagnosed with PD and even though both were already diseased and could not be examined, the medical history provided by the index patient was in accordance with idiopathic PD. Regarding the phenotypic spectrum of known *SNCA* missense mutations, manifestations that are indistinguishable from idiopathic PD as well as atypical and more complex syndromes have been described (*29*). While atypical symptoms are for example

346 common in carriers of G51D (18, 52), they are rarely described in carriers of A30P and A30G (22, 53). Additionally, both A30P and A30G seem to lead to an overall more benign disease 347 course compared to other missense mutations, which is similar to our identified mutation. 348 However, cognitive decline was a common feature in both carriers of A30P and A30G and could 349 even precede the onset of motor-symptoms, which was not observed in our present case. Another 350 feature that is often seen across all SNCA mutations (including multiplications) are motor-351 fluctuations, that are present in around tree thirds of cases (26). In the patient with K58N, the 352 severity of motor- fluctuations eventually led to the implantation of bilateral nucleus 353 354 subthalamicus DBS. The patient profited from this intervention, with a good overall effect on motor-symptoms and motor-fluctuations. Thus, our study provides valuable information about 355 beneficial DBS in K58N SNCA, even though the long-term effect has yet to be assessed, as 356 motor-fluctuations seemed to re-emerge 4 years after DBS. A growing body of research suggest 357 that the outcome of DBS is influenced by the presence of different genetic mutations (54). So far, 358 data on DBS in SNCA missense variants is rare and limited to a few cases, with variable results 359 (22, 55–58). Whilst all cases had good short-term benefits from subthalamic nucleus DBS, 360 especially on motor-fluctuations, two unrelated patients with A53E experienced rapid progression 361 of motor- and non-motor symptoms after surgery (55, 57). Re-emergence of motor-fluctuations 362 after DBS was also reported in two patients with A30G (after 3 years) (22) and E46K (unknown 363 interval) (58), respectively, but both cases had an overall less aggressive progression than the 364 A53E cases. Additional data is needed to elucidate the relationship between SNCA mutations and 365 DBS outcome, as this has important implications for patient counseling and indication for DBS. 366 Most aSyn PD-associated mutations identified thus far occur in the N-terminal domain of aSyn. 367

This region plays a crucial role in the interaction of a Syn with lipids and biological membranes. Binding to membranes is mediated through the repeated KTKEGV motif that is essential for the formation of an amphipathic α -helical structure needed for the interactions with membranes,

371 which ultimately affect several structural and functional aspects of aSyn in cells. For example, aSyn exists, under normal conditions, in a dynamic equilibrium between its cytosolic soluble 372 disordered form and helically structured membrane-bound conformations (59, 60). Interestingly, 373 most PD known mutations are present in the N-terminal domain region of aSyn leading to 374 conformational alterations affecting its helical propensity, and therefore its preferential binding to 375 membranes versus its solubility in the cytosol, und ultimately functional and pathological 376 properties (47, 61). The K58N mutation is also located in the N-terminal region and, more 377 importantly, within the KTKEGV sequence. Lysines (K) are charged residues that play important 378 379 role in the formation of amphipathic α -helices by establishing electrostatics interactions the with negatively charged heads of the lipids in the membranes. The replacements of the charged residue 380 (K) within the KTKEGV sequence with uncharged residue asparagine (N) is expected to disrupt 381 α -helix formation and electrostatic interactions with membranes (62). Furthermore, asparagine 382 residues tend to occur in bends, turns and random coils. Consistently, our NMR data showed a 383 local effect for the K58N mutation that was found mainly around the mutation site, which 384 decrease the α -helical content of residues A53-N65. Simulation data were complementary to 385 NMR findings, further supporting the idea that the K58N mutation disrupts the helical propensity 386 of aSyn around the mutation site. The mutation-induced alterations in conformational dynamics 387 are expected therefore to influence several functional properties for aSyn including its interactions 388 with membranes. Despite this, the extent to which each PD-associated mutation alters membrane 389 390 binding can differ from one mutation to another mutation, and can be influenced by other factors including the lipid composition and the curvature of those membranes. Among PD mutations, 391 A30P is known to exhibit defective binding to membranes due to its decreased helical propensity 392 393 (63, 64). In the current study, we observed that the α -helical propensity for K58N is reduced in the presence of liposomes when compared to WT aSyn, consistent with a lower affinity of K58N 394 to lipids. 395

396 A central pathological hallmark of various synucleinopathies is misfolding and aggregation of aSyn into insoluble and fibrillar protein deposits. Furthermore, different fibrils strains have been 397 observed in certain synucleinopathies. Therefore, we investigated the impact of the K58N 398 mutation on aSyn assembly. Importantly, the mutation occurs in a residue that is very close the 399 central hydrophobic domain which plays a crucial role in the aggregation of aSyn. Furthermore, 400 the local effects induced by this mutation were not limited to the immediate proximity of the 401 mutation site but also residues further away, including some in the beginning of the central 402 hydrophobic domain. According to different aggregation prediction algorithms, it is expected that 403 404 K58N mutant aSyn exhibits higher aggregation propensity. Interestingly, this is consistent with our experimental in vitro aggregation assays that showed increased ThT binding and different 405 aggregation kinetics when compared to WT aSyn. It is possible that the positively charged K at 58 406 407 position protects against aggregation, and that this effect is lost once it is mutated to a neutral N residue. This is consistent with data from studies of the H50Q mutation, as both substitutions have 408 similar charge effects. Histidine at position 50 carries a partial positive charge at neutral pH, and 409 it is substituted by a neutral Q leading to increased aggregation tendency in vitro (65, 66). 410

The observed changes may also reflect differences in the structural characteristics of the fibrils 411 between WT and K58N aSyn. The findings from cryo-EM data revealed that the K58N mutation 412 preferentially results in 2PF fibrils with a similar protofilament fold than WT fibrils, suggesting 413 that the mutation stabilizes the WT inter-protofilament interface. One possibility is that K58 414 415 modulates the ability of the adjacent interface-stabilizing residue (E57) to interact in cis or trans. In WT, K58 may form a salt bridge in cis with E57, which could destabilize the inter-416 protofilament interface and thereby favour 1PF structures. In contrast, the K58N mutation may 417 prevent this interaction due to the altered charge properties, thereby promoting trans interactions 418 with K45 of an adjacent protofilament and thus favoring in 2PF fibrils. Interestingly, the effects of 419 the K58N mutation are opposite to those we recently reported for the G14R mutation (24), which 420

strongly favors 1PF forms. Altogether, these results indicate that the main effect of these
mutations in fibril architecture is the modulation of the WT conformational landscape, favoring
either 1PF (G14R) or 2PF (K58N) forms.

In cells, K58N aSyn formed fewer inclusions when compared to WT aSyn and, overall these inclusions were smaller. These data are not surprising as some aSyn mutations previously studied showed, for example, attenuated aSyn aggregation in vitro while exhibiting increased formation of cellular inclusions (24, 47). The findings using the yeast model revealed a more diffuse cytoplasmic distribution, further demonstrating the importance of employing diverse experimental models when evaluating the effects of mutations in the behaviour of aSyn, as this will likely uncover different properties of the protein.

The process of aSyn phase separation, leading to the formation of condensates (67, 68), is 431 considered dynamic under physiological conditions, but it has been shown that aSyn phase 432 separation, under certain pathological states, can result in the formation of precursors or seeds that 433 transform into solid, insoluble pathological aggregates (69-71). More recently, it has been shown 434 that aSyn phase separation and condensate formation is regulated by VAMP2 (48, 72), and that 435 this regulatory mechanism may rely on the binding of aSyn to lipid membranes (48). In this assay, 436 the A30P aSyn mutant, which is typically known for its defective lipid-binding properties (62, 437 73–75) and increased cytoplasmic localization (50, 76), failed to form condensates in cells. 438 Interestingly, several assays conducted here revealed that the K58N mutant exhibits disrupted 439 440 binding to membranes and increased cytosolic distribution, similarly to what was observed with A30P. 441

The phosphorylation of aSyn at serine 129 (pS129), previously recognized as pathological hallmark (*33*), is increasingly considered to also play a physiological role (*34*, 77). This phosphorylation is a dynamic and reversible neuronal activity-dependent process that increases when neurons are stimulated, and is reversed when neuronal activity is reduced (*34*). In our study,

we observed similar patterns of activity-dependent pS129 for both WT and K58N aSyn, in agreement with previous findings for some PD-associated mutations (*24*, *49*). These findings are consistent with different pathological effects by different mutations, and is consistent with a more benign disease course in the affected patient. Nevertheless, our study points to the importance of assessing the dynamic reversibility of S129 phosphorylation, as this sheds light into the molecular effects of aSyn mutations.

In conclusion, we report the identification of a novel heterozygous *SNCA* mutation, encoding for K58N aSyn, that is characterized clinically by causing early onset, and a benign course of PD that showed good response to DBS. The mutant protein was found to exhibit unique molecular and functional properties, such as reduced helical propensity, impaired lipid binding, increased solubility, and reduced condensation and inclusion formation in cells. Ultimately, our findings advance our understanding of the biology and pathobiology of aSyn, and provide new insight into the molecular mechanisms underlying PD and other synucleinopathies.

459

460 Materials and methods

The patient was evaluated by neurologists specialized in movement disorders at the tertiary 461 movement disorder center Paracelsus Elena-Klinik, Kassel, Germany. Repeated general and 462 neurologic examinations included assessment of motor-symptoms by UPDRS, cognition by 463 MMST, standardized levodopa challenge as described previously. Written informed consent was 464 given by the patient to participate in a genetic study in cooperation with the Institute of Human 465 Genetics, Technical University Munich, Germany. The study was approved by local ethic 466 committees. Additional consent to confirm the genetic finding at the Institute of Human Genetics, 467 University Clinic Göttingen, Germany was provided. Deep brain surgery (DBS) was performed at 468 the Clinic of Neurosurgery, University Medical Center Göttingen, Germany. 469

470

471 Genetic testing

Whole-exome sequencing (WES) was performed at the Institute of Human Genetics at the 472 Technical University of Munich, Germany, Genomic DNA was extracted from peripheral blood 473 according to standard protocols. In-solution enrichment of targeted regions was accomplished 474 using the Sure Select Human All Exon Kit (Agilent 60mb V6) and followed by paired-end 475 sequencing of 100 base pare (bp) long reads with the Illumina NovaSeq6000 system (Illumina, 476 San Diego, California). Average exome coverage was 102x, with 97% of the target regions being 477 covered at least 20x. The whole SNCA region was covered >20x (average depth 80x). The 478 479 mutation was confirmed in an independent blood sample by Sanger sequencing by the Human genetics Department at the University Medical Center Göttingen. 480

481

482 Expression and purification of recombinant WT and K58N aSyn

The K58N mutation was incorporated into the bacterial plasmid encoding aSyn using through 483 site-directed mutagenesis (QuikChange II, Agilent), and Sanger sequencing was used to validate 484 the presence of the mutation. The production of recombinant proteins was performed in 485 BL21(DE3) E. coli cells that were transformed with pET21A vectors encoding either WT or 486 G14R aSyn, following established protocols (78). After extracting proteins from bacterial pellets, 487 they were purified through sequential anion-exchange and size-exclusion chromatography (SEC) 488 for use in aggregation assays, nuclear magnetic resonance (NMR) analysis, and lipid binding 489 490 experiments. The purified proteins were concentrated in PBS buffer (pH 7.4), sterile-filtered, and stored at -80°C until further use. For NMR studies, the SEC buffer was replaced with 100 mM 491 NaCl, 50 mM HEPES, pH 7.4. Determination of proteins concentration was done by measuring 492 493 absorbance at 280 nm, applying an extinction coefficient of 5,960 M⁻¹cm⁻¹.

494

495 **Liposome preparation**

496	5 mg of 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE):1,2-dioleoyl-sn-glycero-3-
497	phospho-L-serine (DOPS):1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) 5:3:2 w/w (Avanti
198	Polar Lipids) were resuspended in 0.8 mL methanol:chloroform 1:1, evaporated under a nitrogen
199	stream, lyophilized o/n and resuspended in 0.52 mL of HEPES buffer (50 mM HEPES, 100 mM
500	NaCl, pH 7.4, 0.02% NaN ₃). The resulting turbid sample was sonicated until transparency (15
501	minutes, 10" on, 20" off).

502

503 Circular dichroism (CD) spectroscopy

Individual WT and K58N aSyn-to-lipid ratios were pipetted (ratio: 1:10, 1:20, 1:40, 1:100 and 504 1:200) at a protein concentration of 50 µM and the respective lipid concentrations from a 12.5 505 mM liposome stock in HEPES buffer (50 mM HEPES, 100 mM NaCl, pH 7.4, 0.02% NaN₃) to a 506 total volume of 12 μ L. For CD measurement the sample was diluted in 48 μ L deionized water and 507 transferred to a 0.02 cm pathlength FireflySci cuvette for a final protein concentration of 10 μ M. 508 CD data were collected from 190 to 260 nm by using a Chirascan-plus qCD spectrometer 509 (Applied Photophysics, Randalls Rd, Leatherhead, UK) at 20 °C, 1.5 time-per-point (s) in 1 nm 510 steps. The datasets were averaged from three repeats. All spectra were baseline corrected against 511 buffer in deionized water and smoothened (window size: 8). 512

513

514 NMR spectroscopy

515 NMR experiments were measured on a Bruker 900 MHz spectrometer equipped with a 5 \Box mm 516 triple-resonance, pulsed-field z-gradient cryoprobe. Two-dimensional ¹H,¹⁵N and ¹H,¹³C 517 heteronuclear single quantum coherence (HSQC) and ¹H,¹H total correlation spectroscopy 518 (TOCSY) experiments were acquired for monomer characterization at 15 °C. All experiments 519 were performed in HEPES buffer (50 mM HEPES, 100 mM NaCl, pH 7.4, 0.02% NaN₃) with 5 520 % (v/v) D₂O. Spectra were processed with TopSpin 3.6.1 (Bruker) and analyzed using Sparky 5115 (T. D. Goddard and D. G. Kneller, SPARKY 3, University of California, San Francisco).

The combined HN/N chemical shift perturbation was calculated according to $(((\delta HN)^2 + (\delta N/10)^2)/2)^{1/2}$. Secondary structure was calculated subjecting the experimental HA, CA, HN and N chemical shifts to TALOS-N (79).

525

526 Molecular dynamics simulations

Starting structures of the aSyn WT and K58N peptides (residues 51-65) were built in the PyMOL 527 Molecular Graphics System (Version 1.8.4.0, Schrödinger, LLC). Initially, the peptides were 528 equilibrated in a water box with 50,000 steps of energy minimization. To further equilibrate the 529 530 system, 100 ps each of volume (NVT) and pressure (NPT) equilibration were performed without position restrains. The MD simulations were carried out in GROMACS (version 2018.3) using the 531 AMBER99SB-ILDN force field and the TIP3P water model at a temperature of 300 K, 1 bar of 532 pressure and with a coupling time (ζ T) of 0.1 ps. The peptides were solvated in water with 150 533 mM NaCl, ensuring overall charge neutrality. The particle mesh Ewald algorithm was used for 534 calculation of the electrostatic term, with a radius of 16 Å for the grid-spacing and Fast Fourier 535 Transform. The cut-off algorithm was applied for the non-coulombic potential with a radius of 10 536 Å. The LINCS algorithm was used to contain bonds and angles. MD simulations were performed 537 during 100 ns in 2 fs steps and saving the coordinates of the system every 10 ps. The α -helical 538 content over the simulation trajectory was analyzed using the PyMOL Molecular Graphics 539 System. Error bars were calculated from the results of 40 peptides (5 peptides in the water box of 540 541 8 independent simulations).

542

543 In vitro thioflavin T fluorescence-based aggregation assays

For the ThT aggregation kinetics assay setup, lyophilized protein was reconstituted in sterile filtered bidistilled water. To get rid of any potential aggregates in protein solutions, samples were first centrifuged at 14,000 rpm for 5 minutes in 100 kDa MWCO filter tubes (Sigma-Aldrich,

547 MO, USA) to collect the filtrate containing monomeric aSyn. Protein concentration was determined on an LVis Plate (BMG Labtech; Ortenberg, Germany) using a CLARIOstar Plus 548 plate reader (BMG Labtech; Ortenberg, Germany) employing the previously mentioned extinction 549 coefficient for aSyn. Prior to initiating the assay, a master mix of 0.5 mg/mL WT or K58N aSyn 550 was prepared in 150 mM NaCl, 10 mM PBS (pH 7.4), 1 mM EDTA, 0.002% SDS, and 25 uM 551 ThT, with 100 µL added into each well in quadruplicate per condition, in addition to the use of 552 protein-free master mix as a blank. The aggregation assay was conducted using CLARIOstar Plus 553 plate reader (BMG Labtech, Ortenberg, Germany) and Costar black, clear-bottom 96-well half-554 555 area plates with preloading a single 1-mm glass bead to each well. Plates were sealed with microplate tape and transferred to the reader, with the following settings: orbital shaking (60 556 seconds on, 30 seconds off) at 400 rpm, 37 °C, in 3.66 min cycles for a total of 1,000 cycles. ThT 557 fluorescence was measured at the end of each cycle with bottom optics, excitation at 450 ± 10 nm, 558 and emission at 480 ± 10 nm. Aggregation curves were then blank-corrected and normalized to 559 the maximum fluorescence for each run. 560

561

562 Cryo-EM imaging and analysis of WT and K58N fibrils

563 Cryo-EM sample Preparation

Copper 200 mesh R2/1 Quantifoil grids were plasma cleaned for 45 seconds at medium power using a Harrick Plasma PDC-32G-2 plasma cleaner and then mounted on a Vitrobot Mark IV (Thermo Fisher). Alpha-synuclein fibrils, prepared at a concentration of 0.5 mg/mL in 30 mM Tris-HCl buffer at pH 7.5, were sonicated in a waterbath sonicator for 10 minutes on medium settings with a 0.5s ON/OFF interval. Shortly thereafter a 3 mL aliquot of the fibrils was applied to the grid. Blotting was performed with a blot force of 7 for 5 seconds. During the freezing process, the Vitrobot chamber was kept at 10°C with 100% humidity.

571 Data Collection

572 Cryo-EM datasets were acquired using a Titan Krios electron microscope (Thermo Fisher) equipped with a Falcon4i detector operated in counting mode. For this study, we collected a 573 dataset for the K58N aSyn mutant under the described conditions and used a previously acquired 574 WT dataset, originally collected as part of the G14R study, as a control. Both datasets were 575 collected at a nominal magnification of 130,000x, vielding a pixel size of 0.92 Å. The K58N 576 dataset consisted of 5,813 movies, while the WT dataset comprised 4,092 movies. The defocus 577 range for both datasets was maintained between -1.2 and $-2.4 \,\mu\text{m}$. A total electron dose of 40 e⁻ 578 $|Å^2$ was applied, with exposures of 6.59 e⁻/Å²s for the WT dataset and 6.61 e⁻/Å²s for the K58N 579 580 dataset. An energy filter with a 15 eV slit width was employed during data collection.

581 Data Processing

The raw EER movies were fractionated, aligned, and summed using MotionCor2 with a dose per 582 frame of 1 e⁻/Å². Contrast transfer function (CTF) parameters were estimated using CTFFIND4. 583 To select segments for both the WT and K58N datasets, a crYOLO model was employed, which 584 had been trained on previously grown recombinant aSyn filaments. For this, fibrils from about 50 585 micrographs of a previous WT aSyn dataset were manually picked in RELION-4, and the 586 coordinates were exported to train a picking model in crYOLO. This model was subsequently 587 used to automatically pick fibrils across all micrographs. The filament coordinates were imported 588 into RELION and used to extract helical segments with an inter-box spacing of approximately 15 589 Å, corresponding to three asymmetric units per segment. Segments were first extracted with a box 590 591 size of 768 pixels, binned three times to a final box size of 256 pixels, and then subjected to 2D classification. After excluding picking artifacts, such as carbon edges, the remaining particles 592 were used to extract unbinned segments with a box size of 384 pixels and a pixel size of 0.92 593 594 Å/px. Another round of 2D classification was performed, and only the classes showing betasheets were selected for further analysis. In case of 1 protofilament (PF) classes for the K58N 595 dataset, no further classifications were carried out since class averages did not show betasheets. 596

.

597	Segments of the selected classes underwent 3D classifications, during which helical parameters
598	were systematically scanned as the crossover distance was not visible in the micrographs and the
599	twist could not be determined directly. Multiple 3D classifications were carried out with a fixed
500	helical rise of 4.75 Å and a twist ranging from -0.5° to -1.7° in roughly 0.05° increments. A
501	featureless cylinder was used as the initial model. Classes showing distinct polypeptide signals
502	were utilized as initial models for subsequent 3D refinements that were performed using a
503	sampling interval of 1.8° and a T-value of 15 to 30. Postprocessed models were then used for
504	CTF refinements and final 3D refinements to optimize resolution and model quality.

505

506 **aSyn aggregation studies in cells**

507 Cell culture

Human neuroglioma cells (H4) were maintained in Opti-MEM I Reduced Serum Medium (Life
Technologies- Gibco, Carlsbad CA, USA) supplemented with 10% Fetal Bovine Serum Gold
(FBS) (PAA, Cölbe, Germany) and 1% Penicillin-Streptomycin (PAN, Aidenbach, Germany).

511 The cells were grown at 37°C in an atmosphere of 5% CO2.

512 Cell Transfection

Twenty-four hours prior to transfection, approximately 80000 H4 cells were plated per well in a 12-well plate (Costar, Corning, New York, USA). Six hours prior to transfection, the medium was replaced with a fresh one. Transfection protocol using Fugene methodology was carried out as described by the manufacturer. Briefly, ratio of 1 (equal amounts of the plasmids encoding SynT Wild Type Kozak or SynT K58N Kozak with/without Synphilin-1-V5) :3 (Fugene solution) mix was prepared in Optimem medium without adds. The mix was incubated for 20 min and added dropwise to the cells while the plate was gently rocked.

520 Immunocytochemistry

521 Forty hours after transfection, the medium was removed, the cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 30 minutes at room temperature (RT). Cell 522 permeabilization with 0.1% Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA) for 20 minutes at 523 RT was performed, followed by blocking in 3% Bovine serum albumin (Nzytech, Lisbon, 524 Portugal) in PBS 1x for 1 hour. Afterwards, cells were incubated with primary antibody mouse 525 anti-ASYN (1:1000, BD Transduction Laboratory, New Jersey, USA) overnight and secondary 526 antibody Alexa Fluor 488 goat anti-mouse (Life Technologies- Invitrogen, Carlsbad, CA, USA) 527 for 2 hours at RT. Finally, cells were stained with DAPI (Carl Roth, Karlsruhe, Germany) (1:5000 528 529 in PBS 1x) for 10 minutes, and the coverslips mounted in SuperFrost[®] Microscope Slides treated with Mowiol (Calbiochem, San Diego, CA) dried and stored at room temperature until further 530 visualization and analysis. Images were acquired using a confocal point-scanning microscope 531 (Zeiss LSM 900 with Airyscan, Carl Zeiss, Jena, Germany). For each condition, 50 images of the 532 10 slices Z-Stack were taken using the 63x objective (Objective Plan-Apochromat 63x/1.4 Oil 533 DIC M27) and specific definitions for each staining in the ZEN Software (Carl Zeiss, Jena, 534 Germany). To quantify the number of aggregates and the size of the aggregates (area of the 535 inclusions) inside the cells, the aSyn channel was selected and the images were thresholded The 536 images were then analysed using the Analyse particle plugin from Fiji open-source software (80). 537

538

539 Solubility and dynamic pS129 reversibility experiments

Plasmids and lentivirus production: synthetic cDNA sequences encoding WT or K58N aSyn were digested at the SpeI/NotI enzymes restriction sites and then ligated into pLVX-EF1a-IRES ZsGreen1 vector (TaKaRa) for their expression, driven by the EF1a promoter. Lentiviral packaging was carried out in 293-T cells as previously described (*34*). Briefly, 293-T cells were transfected with plasmids encoding WT or K58N aSyn along with the packaging plasmids pMD2.G and psPAX2 (Addgene #12259 and #12260). After transfection, the viral particles from

546 the culture supernatant were collected, and subjected to ultracentrifugation at 100,000g for obtaining purified/concentrated viral particles. The purified viral pellet then reconstituted in 547 neurobasal medium containing B-27 and Glutamax (Gibco), resulting in a yield around 2.5×10^6 548 viral particles per uL. To investigate the impact of K58N mutation on phosphorylation status of 549 aSyn at S129, we cultured primary cortical neurons from E18 pregnant SNCA knockout 550 (SNCA-/-) rats on 24-well plates previously coated with poly-d-lysine, and induced the 551 expression of human WT or K58N proteins by lentiviral transduction at DIV5 as described (49). 552 To assess the solubility of aSyn of K58N vs. WT aSyn, we performed sequential protein 553 554 extraction to isolate cytosol (C) vs. membrane (M) protein fractions using the on-plate extraction technique as previously described (81). For the experiments assessing dynamic reversibility of 555 pS129, cortical cultures were treated at DIV17-21 with vehicle (DMSO), 20 µM picrotoxin 556 (PTX), 1µM tetrodotoxin (TTX), or combination of both PTX and TTX. Following treatment for 557 2h or 4h intervals, cell lysis and immunoblotting was conducted to measure the levels of total and 558 pS129 aSyn as previously described (34, 49). For this study, at least three independent 559 experiments were carried out on different days, with a total of 10-16 biological replicates. Data 560 presented in Fig. 6 B, D, and I-L are statistically analyzed by an unpaired *t*-test with Welch's 561 correction, while data in F-G were analyzed by Brown-Forsythe and Welch ANOVA with 562 Dunnett's T3 post hoc test for multiple comparisons. Data in Fig. 6 H were analyzed by a two-563 way ANOVA with Šídák's multiple comparisons test. Please note: In the experiments assessing 564 the solubility and dynamic reversibility of pS129, both G14R (24) and G58N mutants were 565 characterized in parallel. Consequently, the data points for WT-aSyn are identical across both sets 566 of experiments (Fig. 6 D, F, H, I, J, K, and L). 567

568

aSyn expression and purification for phase separation studies

570 Recombinant wild-type and K58N human full-length aSyn was expressed in BL21(DE3) competent Escherichia coli (C2527, NEB, Ipswich, US) using vector pET28a (Addgene 571 #178032). Bacteria were cultured in LB media supplemented with 50 µg/mL kanamycin (37 °C, 572 constant shaking at 250 rpm). Expression was induced at an OD600 of 0.8 using 1mM isopropyl 573 β-D-1-thiogalactopyranoside (IPTG) and cultured overnight at 25 °C. Cell pellets were harvested 574 by centrifugation at 4000 × g for 30 minutes (AVANTI J-26, Beckman Coulter, USA). aSyn was 575 purified using a protocol previously described (2). Briefly, the cell pellet was resuspended in lysis 576 buffer (10 mM Tris, 1 mM EDTA, Roche cOmplete EDTA free protease inhibitor cocktail, pH 8). 577 578 The cells were disrupted using a cell disruptor (Constant Systems, Daventry, UK) and were ultracentrifuged at 4 °C, 186,000 × g for 20 minutes (Ti-45 rotor, Optima XPN 90, Beckman 579 Coulter, USA). The supernatant was collected and heated for 20 minutes at 70 °C to precipitate 580 heat-sensitive proteins, followed by ultracentrifugation as above. Streptomycin sulfate (5711, 581 EMD Millipore, Darmstadt, Germany) was added at a final concentration of 10 mg/mL to the 582 supernatant and continuously stirred at 4 °C for 15 minutes to precipitate DNA, followed by 583 ultracentrifugation as above. Ammonium sulfate (434380010, Thermo Scientific) was added at a 584 final concentration of 360 mg/mL to the supernatant and continuously stirred at 4 °C for 30 585 minutes to precipitate the protein. The precipitated protein was then centrifuged at $500 \times g$ for 15 586 min, dissolved in 25 mM Tris, pH 7.7, and dialyzed overnight against the same buffer to remove 587 salts. The protein was purified using ion exchange on a HiTrapTMO HP 5mL anion exchange 588 column (17115401, Cytiva, Sweden) using gradient elution with 0-1M NaCl in 25 mM Tris, pH 589 7.7. The collected protein fractions were run on SDS-PAGE and pooled fractions were further 590 purified using size-exclusion chromatography on a HiLoadTM 16/600 SuperdexTM 75 pg 591 592 column (28989333, Cytiva, Sweden). The fractions were collected, and their purity was confirmed using SDS-PAGE analysis. Protein concentrations were determined by measuring 593 absorbance at 280 nm using an extinction coefficient of 5,600 M⁻¹ cm⁻¹. The monomeric protein 594

595 was frozen in liquid nitrogen and stored in 25 mM HEPES buffer pH 7.4 at -70 °C. pET28a Cdk2ap1CAN gift from Lin He (Addgene plasmid # 178032; 596 was a http://n2t.net/addgene:178032; RRID:Addgene 178032) (3). 597

598

599 **aSyn labelling**

Labelling of aSyn was performed in bicarbonate buffer (C3041, Sigma) at pH 8 using NHS-ester active fluorescent dye AlexaFluor 488 5-SDP ester (A30052, Invitrogen Thermo Fisher). Excessfree dye was removed by buffer exchange using PD10 desalting columns (IP-0107-Z050.0-001, emp BIOTECH, Generon). Labelled protein concentrations were estimated using the molar extinction coefficient ε 494 nm = 72,000 \square M⁻¹ cm⁻¹.

705

706 aSyn phase separation assays

All aSyn phase separation assays were performed in 25 mM HEPES, pH 7.4 unless mentioned 707 otherwise. Phase separation was induced by mixing aSyn and PEG-8000 (BP223, Fisher 708 Bioreagent) in the presence of calcium (21108, Sigma) as indicated. Images for phase-separated 709 samples were acquired on an LSM780 confocal microscope (Zeiss, Oberkochen, Germany) using 710 a 63x oil immersion objective. Zen 2.3 (black edition) and Zen 2.6 (blue edition) were used for 711 data collection and image export. Images were taken at the indicated aSyn concentration, where 712 aSyn was supplemented with 1% Alexa 488 labelled aSyn. For turbidity measurements phase 713 714 separation samples were set up as described above using indicated concentrations of aSyn and PEG-8000 in the presence of calcium (21108, Sigma). The turbidity of the samples was measured 715 at 350 nm, 25 °C using 96-well Greiner optical bottom plates on a CLARIOstar plate reader 716 (BMG LABTECH, Ortenberg, Germany) under quiescent conditions. CLARIOStar 5.01 was used 717 for data acquisition. A sample volume of 100 μ L was used, and readings were taken within 5 718

- 719 minutes of sample preparation. Raw turbidity data are plotted with background subtraction using
- 720 GraphPad Prism 9.3.1. Data were obtained from four independent repeats.
- 721

722 Plasmids

Wild-type human full-length SNCA and VAMP2, encoding aSyn and VAMP2, were cloned from cDNA obtained from human neuroblastoma cells (SH-SY5Y) and inserted into the pEYFP-N1 and pMD2.G vector (Addgene #96808, #12259) with a C-terminal YFP and Flag-tag, respectively. aSyn K58N was generated using KLD substitution (M0554S, NEB, Ipswich, US). All sequences were verified by sequencing. 5HT6-YFP-Inpp5e was a gift from T. Inoue (Addgene plasmid 96808; RRID: Addgene_96808)128. pMD2.G was a gift from D.Trono (Addgene plasmid 12259; RRID: Addgene_12259).

730

731 Cell culture and transfection

HeLa cells were obtained from the European Collection of Cell Cultures (ECACC 93021013) and 732 grown in Dulbecco's modified Eagle's Medium (DMEM) high glucose (31966-021, Gibco) 733 supplemented with 10% fetal bovine serum (FBS, F7524, Sigma) and 1% Penicillin/Streptomycin 734 (P0781, Sigma). Cells were grown at 37 °C in a humidified incubator with 5% CO2. Cells were 735 tested for mycoplasma contamination using MycoStripTM (IvivoGen, Toulouse, France). Cells 736 were plated at 20,000 cells/well in 8-well ibidi dishes (80807, ibidi, Gräfelfing, Germany) for 737 confocal imaging or in 48-well plates (Cellstar, 677 180, Greiner bio-one) for incuCyte 738 experiments. Cells were transfected the following day using Fugene HD Transfection reagent 739 according to the manufacturer's protocol (E2311, Promega). Briefly, per reaction 12.5 µL 740 741 OptiMEM (31985-062, Gibco) were set up in 1.5 mL sterile Eppendorf tubes. A total of 250 ng of DNA and 0.75 µL of Fugene reagent were added and incubated for 15 min at room temperature. 742

The transfection mix was added to the cells for 1 min and then topped up with 300 μ L complete media. Cells were imaged the next day.

745

746 Confocal microscopy and IncuCyte

Live cell confocal imaging was performed on an LSM780 microscope (Zeiss, Oberkochen, 747 Germany) using a 63x oil immersion objective. YFP fluorescence was excited with the 514 laser 748 at 2% laser power. Zen 2.3 (black edition) and Zen 2.6 (blue edition) were used for data collection 749 and image export. For quantitative evaluation of condensate formation cells were imaged with the 750 751 IncuCvte S3 (Essen BioScience, Newark, UK). Phase brightfield and green fluorescence images were taken using a 20x objective at a 4-hour interval at 200 ms exposure, condensate formation 752 (% of cells showing condensate formation) was evaluated 16 hours after transfection. IncuCyte 753 2021A was used for data analysis. At least three biological repeats with three technical repeats 754 each were analysed blinded to the investigator. 755

756

757 **Quantification and statistical analysis**

Data analysis and statistical analysis was performed using Excel 2016 and GraphPad Prism 9.3.1. 758 All data are represented as mean ± standard error (SD) if not indicated otherwise. Statistical 759 analysis was carried out using unpaired two-tailed t-test. Statistical parameters are reported in the 760 Fig.s and the corresponding Fig. Legends. Exact p-values are shown. Data distribution was 761 assumed to be normal but this was not formally tested. No statistical methods were used to pre-762 determine sample sizes but our sample sizes are similar to those reported in previous publications 763 (4–6). Samples were randomly allocated into experimental groups. Data collection and analysis 764 have been performed blinded when indicated. Data were included if the control (wild-type) 765 showed appropriate condensate formation. 766

768 Yeast Plasmids

The aSyn-K58N variant was constructed by site-directed mutagenesis using the QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, SC, USA), in the plasmid backbone p426GPD encoding the WT aSyn-GFP, following the manufacturer's instructions. We also constructed a plasmid expressing only GFP as a control, by introducing the GFP coding sequence as a SpeI-XhoI digested PCR product in the p426GPD backbone. All constructs were confirmed by DNA sequencing.

775

776 Yeast cell growth conditions, viability assay and fluorescence microscopy

The Saccharomyces cerevisiae yeast strain BY4741 (MATa his $3\Delta 1 \ leu 2\Delta 0 \ met 15\Delta 0 \ ura 3\Delta 0$) was transformed with GFP, WT aSyn and K58N plasmids by standard lithium acetate method. All strains were grown overnight at 30 °C 180 rpm in yeast minimal synthetic defined (SD) medium (Takara Bio), supplemented with a drop-out mix (Takara Bio) lacking the amino acid uracil (SD-URA) for transformant selection, at a volume/medium ratio of 5:1.

782 The assessment of cellular viability was achieved by spotting assay. Here, cultures grown to mid-

log phase were standardized to equal cellular densities, serially diluted 10-fold starting with an
OD600nm of 1 and spotted on SD-URA agar plates. Following 3 days incubation at 30 °C the
plates were photographed.

- aSyn cellular localization was evaluated by fluorescent microscopy. Images were attained with an
 epifluorescence microscope Zeiss Axio Observer equipped with a 100x oil objective lens.
- 788
- 789
- 790
- 791
- 792

793			
794			
795			
796			
797			
798			
799			
300			
301			
302			
303			
304			

306 Abbreviations

- 307 aSyn Alpha-synuclein
- 308EOPDEarly onset PD
- 309LBDLewy body dementia
- 310 MSA Multiple system atrophy
- 311 PD Parkinson's disease
- 312 SNCA Alpha-synuclein gene
- 313

314 Acknowledgements

We thank Dr. Ellen Gerhardt for assistance with site-directed mutagenesis in the aSyn-encoding plasmids.

- 317
- Mohammed Al-Azzani^{1†}, Sandrina Weber^{2†}, Nagendran Ramalingam³, Maria Ramón¹, Liana
 Shvachiy¹, Gonçalo Mestre¹, Michael Zech^{4,5,6}, Kevin Sicking^{7,8}, Alain Ibáñez de Opakua⁹,
 Vidyashree Jayanthi³, Leslie Amaral^{1,10}, Aishwarya Agarwal¹¹, Aswathy Chandran¹¹, Susana R.
 Chaves¹⁰, Juliane Winkelmann^{4,5,12,13}, Claudia Trenkwalder^{14,15}, Maike Schwager¹⁶, Silke Pauli¹⁶,
 Ulf Dettmer³, Claudio O. Fernández¹⁷, Janin Lautenschläger¹¹, Markus Zweckstetter^{9,18}, Ruben
 Fernandez Busnadiego^{7,8,19,20}, Brit Mollenhauer^{2,15*}, and Tiago Fleming Outeiro^{1,9,21,22*}
- 324

325 Author contributions

- TFO and BM contributed to the study conception and design. MAA, SB, NR, MR, LS, GM, MZ,
- KS, AIO, VJ, LA, AA, and AC contributed to the acquisition of data.
- MAA, SB, NR, KS, UF, JL, MZZ, CF, JW, CT, MS, SP, RFB, BM, and TFO analyzed and
- interpreted the data.

MAA, SB, and TFO wrote the initial draft of the manuscript. All authors reviewed and revised the manuscript.

332

333 Funding

T.F.O. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research 334 Foundation) under Germany's Excellence Strategy, EXC 2067/1- 390729940, and by SFB1286 335 (B8). J.L. is supported by the Royal Society (Royal Society Dorothy Hodgkin Research 336 Fellowship, DHF/R1/201228), the Addenbrooke's Charitable Trust (Grant Award 900325), the 337 338 Leverhulme Trust (Research Project Grant, RPG-2022-257), as well as a Career Support Fund from the University of Cambridge. L.S. was supported by the Foundation for Science and 339 Technology (FCT), SFRH/BD/143286/2019. N.R. and U.D. are supported by the National 340 Institutes of Health (grant numbers NS121826, NS099328, NS109209, NS122880, and 341 NS133979). M. Zweckstetter is supported by the Michael J. Fox foundation through MJFF-342 022411. M.Zech acknowledges grant support by the European Joint Programme on Rare Diseases 343 (EJP RD Joint Transnational Call 2022), and the German Federal Ministry of Education and 344 Research (BMBF, Bonn, Germany), awarded to the project PreDYT (PREdictive biomarkers in 345 DYsTonia, 01GM2302), by the Federal Ministry of Education and Research (BMBF) and the 346 Free State of Bayaria under the Excellence Strategy of the Federal Government and the Länder, as 347 well as by the Technical University of Munich – Institute for Advanced Study. MZ's research is 348 supported by а "Schlüsselprojekt" grant from the Else Kröner-Fresenius-Stiftung 349 (2022_EKSE.185). 350

R.F.B. is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research
Foundation) under Germany's Excellence Strategy, EXC 2067/1- 390729940, and by SFB1286
(A12). Cryo-EM instrumentation at the University of Göttingen was jointly funded by the DFG
Major Research Instrumentation program (448415290) and the Ministry of Science and Culture of

355	the State of Lower	Saxony. K.S.	and R.FB. v	were funded by	the join	t efforts of	The Michael J.
-----	--------------------	--------------	-------------	----------------	----------	--------------	----------------

Fox Foundation for Parkinson's Research (MJFF) and the Aligning Science Across Parkinson's

- (ASAP) initiative. MJFF administers the grant ASAP-000282 on behalf of ASAP and itself.
- 358

359 Conflict of interests

- 360 The authors declare that they have no competing interests to disclose related to the article.
- 361

362 **Data availability**

All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

The micrographs used for the single-particle analysis (SPA) of alpha-synuclein fibrils are available in the EMPIAR database under accession code EMPIAR-12518.

The atomic model and cryo-EM density map for the wild-type (WT) alpha-synuclein fibril are deposited in the Protein Data Bank (PDB) and Electron Microscopy Data Bank (EMDB) under accession codes 9HGS and EMD-52165, respectively. The corresponding data for the K58N mutant alpha-synuclein fibril are available under accession codes 9HXA (PDB) and EMD-52458 (EMDB).

A comprehensive Key Resource Table, detailing datasets, software, and protocols is available via Zenodo at https://zenodo.org/records/14730688. Additionally, the entry includes an Excel file with tabular data on the protofilament distribution of WT and K58N alpha-synuclein filaments, XML files containing tabular data for the FSC graphs of each density map used to determine the final resolution (generated with RELION 4.0), and two Python scripts for graphing the FSC XML data.

878	The full single-particle analysis protocol describing the cryo-EM data processing strategy is
879	available at Protocols.io (https://www.protocols.io/view/single-particle-analysis-of-synuclein-
380	fibrils-81wgbxozylpk/v1).

- 381
- 382
- 383
- 384 **References**
- 1. M. Flores-Leon, T. F. Outeiro, More than meets the eye in Parkinson's disease and other synucleinopathies: from proteinopathy to lipidopathy. *Acta Neuropathol* **146**, 369–385 (2023).
- R. B. Postuma, D. Berg, M. Stern, W. Poewe, C. W. Olanow, W. Oertel, J. Obeso, K.
 Marek, I. Litvan, A. E. Lang, G. Halliday, C. G. Goetz, T. Gasser, B. Dubois, P. Chan, B.
- R. Bloem, C. H. Adler, G. Deuschl, MDS clinical diagnostic criteria for Parkinson's
 disease. *Movement Disorders* 30, 1591–1601 (2015).
- 392 3. M. H. Polymeropoulos, C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H.
- Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T.
- Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe,
- R. L. Nussbaum, Mutation in the α-synuclein gene identified in families with Parkinson's
 disease. *Science (1979)* 276 (1997).
- M. G. Spillantini, M. L. Schmidt, V. M. Y. Lee, J. Q. Trojanowski, R. Jakes, M. Goedert,
 α-synuclein in Lewy bodies [8]. [Preprint] (1997). https://doi.org/10.1038/42166.
- 5. L. I. Golbe, G. Di Iorio, G. Sanges, A. M. Lazzarini, S. La Sala, V. Bonavita, R. C.
 Duvoisin, Clinical genetic analysis of Parkinson's disease in the Contursi kindred. *Ann Neurol* 40 (1996).

<i>€</i>	6.	S. Appel-Cresswell, C. Vilarino-Guell, M. Encarnacion, H. Sherman, I. Yu, B. Shah, D.
) 03		Weir, C. Thompson, C. Szu-Tu, J. Trinh, J. O. Aasly, A. Rajput, A. H. Rajput, A. Jon
) 04		Stoessl, M. J. Farrer, Alpha-synuclein p.H50Q, a novel pathogenic mutation for
) 05		Parkinson's disease. Movement Disorders 28 (2013).
) 06	7.	M. Schweighauser, Y. Shi, A. Tarutani, F. Kametani, A. G. Murzin, B. Ghetti, T.
) 07		Matsubara, T. Tomita, T. Ando, K. Hasegawa, S. Murayama, M. Yoshida, M. Hasegawa,
) 08		S. H. W. Scheres, M. Goedert, Structures of α -synuclein filaments from multiple system
) 09		atrophy. <i>Nature</i> 585 (2020).
∂ 10	8.	Y. Yang, Y. Shi, M. Schweighauser, X. Zhang, A. Kotecha, A. G. Murzin, H. J. Garringer,
∂ 11		P. W. Cullinane, Y. Saito, T. Foroud, T. T. Warner, K. Hasegawa, R. Vidal, S. Murayama,
<i>€</i> 12		T. Revesz, B. Ghetti, M. Hasegawa, T. Lashley, S. H. W. Scheres, M. Goedert, Structures
) 13		of α -synuclein filaments from human brains with Lewy pathology. <i>Nature</i> 610 (2022).
€914	9.	S. H. W. Scheres, B. Ryskeldi-Falcon, M. Goedert, Molecular pathology of
€915		neurodegenerative diseases by cryo-EM of amyloids. [Preprint] (2023).
) 16		https://doi.org/10.1038/s41586-023-06437-2.
€917	10.	I. C. Brás, M. Xylaki, T. F. Outeiro, "Mechanisms of alpha-synuclein toxicity: An update
€918		and outlook" in Progress in Brain Research (2020)vol. 252.
€919	11.	D. J. Koss, D. Erskine, A. Porter, P. Palmoski, H. Menon, O. G. J. Todd, M. Leite, J.
∂ 20		Attems, T. F. Outeiro, Nuclear alpha-synuclein is present in the human brain and is
) 21		modified in dementia with Lewy bodies. Acta Neuropathol Commun 10 (2022).
) 22	12.	K. Ezzat, A. Sturchio, A. J. Espay, Proteins Do Not Replicate, They Precipitate: Phase
) 23		Transition and Loss of Function Toxicity in Amyloid Pathologies. [Preprint] (2022).
) 24		https://doi.org/10.3390/biology11040535.

) 25	13.	A. J.	Espay.	A. J.	Lees.	Loss	of	monomeric	alpha-s	vnuclein	(s	vnucleinor	penia)) and	the

) 26	origin	of	Parkinson's	disease.	[Preprint]	(2024).
) 27	https://doi.or	g/10.1016	5/j.parkreldis.2024.10	6077.		

) 28	14.	A. Westenberger, V. Skrahina, T. Usnich, C. Beetz, EJ. Vollstedt, BH. Laabs, J. J. Paul,
) 29		F. Curado, S. Skobalj, H. Gaber, M. Olmedillas, X. Bogdanovic, N. Ameziane, N. Schell,
) 30		J. O. Aasly, M. Afshari, P. Agarwal, J. Aldred, F. Alonso-Frech, R. Anderson, R. Araújo,
) 31		D. Arkadir, M. Avenali, M. Balal, S. Benizri, S. Bette, P. Bhatia, M. Bonello, P. Braga-
) 32		Neto, S. Brauneis, F. E. C. Cardoso, F. Cavallieri, J. Classen, L. Cohen, D. Coletta, D.
) 33		Crosiers, P. Cullufi, K. Dashtipour, M. Demirkiran, P. de Carvalho Aguiar, A. De Rosa, R.
) 34		Djaldetti, O. Dogu, M. G. dos Santos Ghilardi, C. Eggers, B. Elibol, A. Ellenbogen, S.
) 35		Ertan, G. Fabiani, B. H. Falkenburger, S. Farrow, T. Fay-Karmon, G. J. Ferencz, E. T.
) 36		Fonoff, Y. D. Fragoso, G. Genç, A. Gorospe, F. Grandas, D. Gruber, M. Gudesblatt, T.
) 37		Gurevich, J. Hagenah, H. A. Hanagasi, S. Hassin-Baer, R. A. Hauser, J. Hernández-Vara,
) 38		B. Herting, V. K. Hinson, E. Hogg, M. T. Hu, E. Hummelgen, K. Hussey, J. Infante, S. H.
) 39		Isaacson, S. Jauma, N. Koleva-Alazeh, G. Kuhlenbäumer, A. Kühn, I. Litvan, L. López-
Э 40		Manzanares, M. Luxmore, S. Manandhar, V. Marcaud, K. Markopoulou, C. Marras, M.
) 41		McKenzie, M. Matarazzo, M. Merello, B. Mollenhauer, J. C. Morgan, S. Mullin, T.
) 42		Musacchio, B. Myers, A. Negrotti, A. Nieves, Z. Nitsan, N. Oskooilar, Ö. Öztop-Çakmak,
) 43		G. Pal, N. Pavese, A. Percesepe, T. Piccoli, C. Pinto de Souza, T. Prell, M. Pulera, J. Raw,
) 44		K. Reetz, J. Reiner, D. Rosenberg, M. Ruiz-Lopez, J. Ruiz Martinez, E. Sammler, B. L.
) 45		Santos-Lobato, R. Saunders-Pullman, I. Schlesinger, C. M. Schofield, A. F. Schumacher-
9 46		Schuh, B. Scott, Á. Sesar, S. J. Shafer, R. Sheridan, M. Silverdale, R. Sophia, M. Spitz, P.
) 47		Stathis, F. Stocchi, M. Tagliati, Y. F. Tai, A. Terwecoren, S. Thonke, L. Tönges, G.
) 48		Toschi, V. Tumas, P. P. Urban, L. Vacca, W. Vandenberghe, E. M. Valente, F. Valzania,
) 49		L. Vela-Desojo, C. Weill, D. Weise, J. Wojcieszek, M. Wolz, G. Yahalom, G. Yalcin-

) 50		Cakmakli, S. Zittel, Y. Zlotnik, K. K. Kandaswamy, A. Balck, H. Hanssen, M. Borsche, L.
∂ 51		M. Lange, I. Csoti, K. Lohmann, M. Kasten, N. Brüggemann, A. Rolfs, C. Klein, P. Bauer,
9 52		Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease
) 53		study. Brain 147, 2652–2667 (2024).
954	15.	L. Cook, J. Verbrugge, TH. Schwantes-An, J. Schulze, T. Foroud, A. Hall, K. S. Marder,
€955		I. F. Mata, N. E. Mencacci, M. A. Nance, M. A. Schwarzschild, T. Simuni, S. Bressman,
956		AM. Wills, H. H. Fernandez, I. Litvan, K. E. Lyons, H. A. Shill, C. Singer, T. F. Tropea,
€957		N. Vanegas Arroyave, J. Carbonell, R. Cruz Vicioso, L. Katus, J. F. Quinn, P. D. Hodges,
€958		Y. Meng, S. P. Strom, C. Blauwendraat, K. Lohmann, C. Casaceli, S. C. Rao, K. Ghosh
€959		Galvelis, A. Naito, J. C. Beck, R. N. Alcalay, Parkinson's disease variant detection and
) 60		disclosure: PD GENEration, a North American study. Brain 147, 2668–2679 (2024).
) 61	16.	K. Daida, S. Shimonaka, K. Shiba-Fukushima, J. Ogata, H. Yoshino, A. Okuzumi, T.
962		Hatano, Y. Motoi, T. Hirunagi, M. Katsuno, H. Shindou, M. Funayama, K. Nishioka, N.
) 63		Hattori, Y. Imai, α -Synuclein V15A Variant in Familial Parkinson's Disease Exhibits a
) 64		Weaker Lipid-Binding Property. Movement Disorders 37 (2022).
€65	17.	R. Krüger, W. Kuhn, T. Müller, D. Woitalla, M. Graeber, S. Kösel, H. Przuntek, J. T.
) 66		Epplen, L. Schöls, O. Riess, Ala30Pro mutation in the gene encoding α -synuclein in
) 67		Parkinson's disease. Nat Genet 18 (1998).
) 68	18.	S. Lesage, M. Anheim, F. Letournel, L. Bousset, A. Honoré, N. Rozas, L. Pieri, K.
) 69		Madiona, A. Dürr, R. Melki, C. Verny, A. Brice, G51D α -synuclein mutation causes a
 €70		novel Parkinsonian-pyramidal syndrome. Ann Neurol 73 (2013).
∂ 71	19.	H. Yoshino, M. Hirano, A. J. Stoessl, Y. Imamichi, A. Ikeda, Y. Li, M. Funayama, I.
€72		Yamada, Y. Nakamura, V. Sossi, M. J. Farrer, K. Nishioka, N. Hattori, Homozygous
) 73		alpha-synuclein p.A53V in familial Parkinson's disease. Neurobiol Aging 57 (2017).

40

- 20. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, J.
- Hoenicka, O. Rodriguez, B. Atarés, V. Llorens, E. Gomez Tortosa, T. Del Ser, D. G.
- Muñoz, J. G. De Yebenes, The New Mutation, E46K, of α-Synuclein Causes Parkinson
 and Lewy Body Dementia. *Ann Neurol* 55 (2004).
- 21. C. Fevga, Y. Park, E. Lohmann, A. J. Kievit, G. J. Breedveld, F. Ferraro, L. de Boer, R.
- van Minkelen, H. Hanagasi, A. Boon, W. Wang, G. A. Petsko, Q. Q. Hoang, M. Emre, V.
- Bonifati, A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with
- Parkinson's disease. *Parkinsonism Relat Disord* **89** (2021).
- 22. H. Liu, C. Koros, T. Strohäker, C. Schulte, M. Bozi, S. Varvaresos, A. Ibáñez de Opakua,
- A. M. Simitsi, A. Bougea, K. Voumvourakis, M. Maniati, S. G. Papageorgiou, A. Hauser,
- S. Becker, M. Zweckstetter, L. Stefanis, T. Gasser, A Novel SNCA A30G Mutation Causes
 Familial Parkinson S Disease. *Movement Disorders* 36, 1624–1633 (2021).
- P. Pasanen, L. Myllykangas, M. Siitonen, A. Raunio, S. Kaakkola, J. Lyytinen, P. J.
 Tienari, M. Pöyhönen, A. Paetau, A novel α-synuclein mutation A53E associated with
 atypical multiple system atrophy and Parkinson's disease-type pathology. *Neurobiol Aging*35 (2014).
- 24. C. Brücke, M. Al-Azzani, N. Ramalingam, M. Ramón, R. L. Sousa, F. Buratti, M. Zech, K.
 Sicking, L. Amaral, E. Gelpi, A. Chandran, A. Agarwal, S. R. Chaves, C. O. Fernández, U.
 Dettmer, J. Lautenschläger, M. Zweckstetter, R. F. Busnadiego, A. Zimprich, T. F. Outeiro,
 A novel alpha-synuclein G14R missense variant is associated with atypical
 neuropathological features. *medRxiv*, doi: 10.1101/2024.09.23.24313864 (2024).
- 395 25. A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S. Hague, J. Kachergus, M. Hulihan,
- 796 T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D.
- ³⁹⁷ Maraganore, C. Adler, M. R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J.

- Hardy, K. Gwinn-Hardy, α-Synuclein Locus Triplication Causes Parkinson's Disease.
 Science (1979) **302** (2003).
- J. Trinh, F. M. J. Zeldenrust, J. Huang, M. Kasten, S. Schaake, S. Petkovic, H. Madoev, A.
 Grünewald, S. Almuammar, I. R. König, C. M. Lill, K. Lohmann, C. Klein, C. Marras,
 Genotype-phenotype relations for the Parkinson's disease genes SNCA, LRRK2, VPS35:
- MDSGene systematic review. [Preprint] (2018). https://doi.org/10.1002/mds.27527.
- T. Konno, O. A. Ross, A. Puschmann, D. W. Dickson, Z. K. Wszolek, Autosomal dominant Parkinson's disease caused by SNCA duplications. *Parkinsonism Relat Disord* 22 (2016).
- 28. C. Blauwendraat, M. B. Makarious, H. L. Leonard, S. Bandres-Ciga, H. Iwaki, M. A.
 Nalls, A. J. Noyce, A. B. Singleton, A population scale analysis of rare SNCA variation in
 the UK Biobank. *Neurobiol Dis* 148 (2021).
- S. Petrucci, M. Ginevrino, E. M. Valente, Phenotypic spectrum of alpha-synuclein
 mutations: New insights from patients and cellular models. *Parkinsonism Relat Disord* 22
 (2016).
- 30. A. Kapasi, J. R. Brosch, K. N. Nudelman, S. Agrawal, T. M. Foroud, J. A. Schneider, A
 novel SNCA E83Q mutation in a case of dementia with Lewy bodies and atypical
 frontotemporal lobar degeneration. *Neuropathology* 40 (2020).
- 31. C. Blauwendraat, D. A. Kia, L. Pihlstrøm, Z. Gan-Or, S. Lesage, J. R. Gibbs, J. Ding, R. N.
- Alcalay, S. Hassin-Baer, A. M. Pittman, J. Brooks, C. Edsall, S. J. Chung, S. Goldwurm,
- M. Toft, C. Schulte, C.-P. C. International Parkinson's Disease Genomics Consortium
-)19 (IPDGC), D. Hernandez, A. B. Singleton, M. A. Nalls, A. Brice, S. W. Scholz, N. W.
- Wood, Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's
- disease. *Neurobiol Aging* **64**, 159.e5-159.e8 (2018).

)22	32.	D.	Papadimitriou,	R.	Antonelou,	M.	Miligkos,	M.	Maniati,	N.	Papagiannakis,	S.

- Bostantjopoulou, A. Leonardos, C. Koros, A. Simitsi, S. G. Papageorgiou, E. Kapaki, R. N.
- Alcalay, A. Papadimitriou, A. Athanassiadou, M. Stamelou, L. Stefanis, Motor and
- Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal
- Study. *Movement Disorders* **31** (2016).
- 33. H. Fujiwara, M. Hasegawa, N. Dohmae, A. Kawashima, E. Masliah, M. S. Goldberg, J.
- Shen, K. Takio, T. Iwatsubo, α-Synuclein is phosphorylated in synucleinopathy lesions.
 Nat Cell Biol 4, 160–164 (2002).
- 30 34. N. Ramalingam, S.-X. Jin, T. E. Moors, L. Fonseca-Ornelas, K. Shimanaka, S. Lei, H. P.
- Cam, A. H. Watson, L. Brontesi, L. Ding, D. Y. Hacibaloglu, H. Jiang, S. J. Choi, E.
- 32 Kanter, L. Liu, T. Bartels, S. Nuber, D. Sulzer, E. V. Mosharov, W. V. Chen, S. Li, D. J.
- Selkoe, U. Dettmer, Dynamic physiological α-synuclein S129 phosphorylation is driven by
 neuronal activity. *NPJ Parkinsons Dis* 9, 4 (2023).
- J. Li, V. N. Uversky, A. L. Fink, Effect of familial Parkinson's disease point mutations
 A30P and A53T on the structural properties, aggregation, and fibrillation of human α synuclein. *Biochemistry* 40 (2001).
- 36. M. B. Fares, N. Ait-Bouziad, I. Dikiy, M. K. Mbefo, A. Jovičić, A. Kiely, J. L. Holton, S.
- J. Lee, A. D. Gitler, D. Eliezer, H. A. Lashuel, The novel Parkinson's disease linked
 mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and
 enhances its secretion and nuclear localization in cells. *Hum Mol Genet* 23 (2014).
- 37. D. F. Lázaro, M. C. Dias, A. Carija, S. Navarro, C. S. Madaleno, S. Tenreiro, S. Ventura,
- T. F. Outeiro, The effects of the novel A53E alpha-synuclein mutation on its
 oligomerization and aggregation. *Acta Neuropathol Commun* 4 (2016).
- 38. T. S. Ulmer, A. Bax, N. B. Cole, R. L. Nussbaum, Structure and Dynamics of Micellebound Human α-Synuclein. *Journal of Biological Chemistry* 280, 9595–9603 (2005).

- 39. W. S. Davidson, A. Jonas, D. F. Clayton, J. M. George, Stabilization of α-Synuclein
- Secondary Structure upon Binding to Synthetic Membranes. *Journal of Biological Chemistry* 273, 9443–9449 (1998).
- D. Eliezer, E. Kutluay, R. Bussell, G. Browne, Conformational properties of α-synuclein in
 its free and lipid-associated states 1 1Edited by P. E. Wright. *J Mol Biol* 307, 1061–1073
-)52 (2001).
- I. Walsh, F. Seno, S. C. E. Tosatto, A. Trovato, PASTA 2.0: an improved server for protein
 aggregation prediction. *Nucleic Acids Res* 42, W301–W307 (2014).
- S. O. Garbuzynskiy, M. Yu. Lobanov, O. V. Galzitskaya, FoldAmyloid: a method of
 prediction of amyloidogenic regions from protein sequence. *Bioinformatics* 26, 326–332
 (2010).
- A. M. Thangakani, S. Kumar, R. Nagarajan, D. Velmurugan, M. M. Gromiha, GAP:
 towards almost 100 percent prediction for β-strand-mediated aggregating peptides with
 distinct morphologies. *Bioinformatics* **30**, 1983–1990 (2014).
- 44. R. Guerrero-Ferreira, N. M. I. Taylor, A. A. Arteni, P. Kumari, D. Mona, P. Ringler, M.
- Britschgi, M. E. Lauer, A. Makky, J. Verasdock, R. Riek, R. Melki, B. H. Meier, A.
 Böckmann, L. Bousset, H. Stahlberg, Two new polymorphic structures of human full-
- length alpha-synuclein fibrils solved by cryo-electron microscopy. *Elife* **8** (2019).
- B. Frieg, L. Antonschmidt, C. Dienemann, J. A. Geraets, E. E. Najbauer, D. Matthes, B. L.
 de Groot, L. B. Andreas, S. Becker, C. Griesinger, G. F. Schröder, The 3D structure of
 lipidic fibrils of α-synuclein. *Nat Commun* 13, 6810 (2022).
- 46. S. Lövestam, M. Schweighauser, T. Matsubara, S. Murayama, T. Tomita, T. Ando, K.
 Hasegawa, M. Yoshida, A. Tarutani, M. Hasegawa, M. Goedert, S. H. W. Scheres, Seeded
 assembly in vitro does not replicate the structures of α-synuclein filaments from multiple
- 371 system atrophy. *FEBS Open Bio* **11** (2021).

172 47. D. F. Lázaro, E. F. Rodrigues, R. Langohr, H. Shahpasandzadeh, T. Ribeiro, P. Guo)72 4'/.	ues, R. Langohr, H. Shahpasandzadeh, T. Ribe	ro. P. Guerreiro
---	----------	--	------------------

- E. Gerhardt, K. Kröhnert, J. Klucken, M. D. Pereira, B. Popova, N. Kruse, B. Mollenhauer,
- 5. O. Rizzoli, G. H. Braus, K. M. Danzer, T. F. Outeiro, Systematic Comparison of the
- ⁰⁷⁵ Effects of Alpha-synuclein Mutations on Its Oligomerization and Aggregation. *PLoS Genet*
- **10**, e1004741 (2014).
- 48. A. Agarwal, A. Chandran, F. Raza, I.-M. Ungureanu, C. Hilcenko, K. Stott, N. A. Bright,
- N. Morone, A. J. Warren, J. Lautenschläger, VAMP2 regulates phase separation of α synuclein. *Nat Cell Biol*, doi: 10.1038/s41556-024-01451-6 (2024).
- N. Ramalingam, L. Brontesi, S. Jin, D. J. Selkoe, U. Dettmer, Dynamic reversibility of αsynuclein serine 129 phosphorylation is impaired in synucleinopathy models. *EMBO Rep*24 (2023).
- 50. T. F. Outeiro, S. Lindquist, Yeast Cells Provide Insight into Alpha-Synuclein Biology and
 Pathobiology. *Science (1979)* **302** (2003).
- S. Richards, N. Aziz, S. Bale, D. Bick, S. Das, J. Gastier-Foster, W. W. Grody, M. Hegde,
 E. Lyon, E. Spector, K. Voelkerding, H. L. Rehm, Standards and guidelines for the
 interpretation of sequence variants: A joint consensus recommendation of the American
 College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine* 17 (2015).
- A. P. Kiely, H. Ling, Y. T. Asi, E. Kara, C. Proukakis, A. H. Schapira, H. R. Morris, H. C.
 Roberts, S. Lubbe, P. Limousin, P. A. Lewis, A. J. Lees, N. Quinn, J. Hardy, S. Love, T.
 Revesz, H. Houlden, J. L. Holton, Distinct clinical and neuropathological features of G51D
 SNCA mutation cases compared with SNCA duplication and H50Q mutation. *Mol Neurodegener* 10 (2015).
- 53. R. Krüger, W. Kuhn, K. L. Leenders, R. Sprengelmeyer, T. Müller, D. Woitalla, A. T.
 Portman, R. P. Maguire, L. Veenma, U. Schröder, L. Schöls, J. T. Epplen, O. Riess, H.

- ⁹⁷ Przuntek, Familial parkinsonism with synuclein pathology: Clinical and PET studies of
- A30P mutation carriers. *Neurology* **56** (2001).
- 54. K. Kalinderi, V. Papaliagkas, L. Fidani, Surgicogenomics: The Role of Genetics in Deep
 Brain Stimulation in Parkinson's Disease Patients. *Brain Sci* 14, 800 (2024).
- 101 55. J. Youn, G. Oyama, N. Hattori, Y. Shimo, T. Kuusimäki, V. Kaasinen, A. Antonini, D.
- 102 Kim, J. Il Lee, K. R. Cho, J. W. Cho, Subthalamic deep brain stimulation in Parkinson's
- 103 disease with SNCA mutations: Based on the follow-up to 10 years. *Brain Behav* **12** (2022).
- M. H. Martikainen, M. Päivärinta, M. Hietala, V. Kaasinen, Clinical and imaging findings
 in Parkinson disease associated with the A53E SNCA mutation. *Neurol Genet* 1 (2015).
- M. Picillo, K. J. Lizarraga, E. L. Friesen, H. Chau, M. Zhang, C. Sato, G. Rooke, R. P.
 Munhoz, E. Rogaeva, P. E. Fraser, S. K. Kalia, L. V. Kalia, Parkinsonism due to A53E αsynuclein gene mutation: Clinical, genetic, epigenetic, and biochemical features. *Movement Disorders* 33 (2018).
- K. Senkevich, I. Miliukhina, A. Zhuravlev, M. Shumilova, M. Beletskaia, T. Skvortsova,
 E. Yu, J. Ahmad, F. Asayesh, Z. Gan□Or, A. Emelyanov, S. Pchelina, Autosomal
 Dominant Parkinson's Disease Caused by <scp> SNCA </scp> p. <scp>E46K</scp>
 Mutation in a Family with Russian Ancestry. *Movement Disorders* **39**, 1424–1425 (2024).
- D. Eliezer, E. Kutluay, R. Bussell, G. Browne, Conformational properties of α-synuclein in
 its free and lipid-associated states. *J Mol Biol* **307** (2001).
- M. Rovere, J. B. Sanderson, L. Fonseca-Ornelas, D. S. Patel, T. Bartels, Refolding of
 helical soluble α-synuclein through transient interaction with lipid interfaces. *FEBS Lett*592, 1464–1472 (2018).
- U. Dettmer, Rationally Designed Variants of α-Synuclein Illuminate Its in vivo Structural
 Properties in Health and Disease. [Preprint] (2018).
 https://doi.org/10.3389/fnins.2018.00623.

- 122 62. R. J. Perrin, W. S. Woods, D. F. Clayton, J. M. George, Interaction of human α-synuclein
- and Parkinson's disease variants with phospholipids: Structural analysis using site-directed
 mutagenesis. *Journal of Biological Chemistry* 275 (2000).
- E. Jo, N. Fuller, R. P. Rand, P. St George-Hyslop, P. E. Fraser, Defective membrane
 interactions of familial Parkinson's disease mutant A30P α-Synuclein. *J Mol Biol* 315
- 127 (2002).
- 64. G. Fusco, T. Pape, A. D. Stephens, P. Mahou, A. R. Costa, C. F. Kaminski, G. S. Kaminski
 Schierle, M. Vendruscolo, G. Veglia, C. M. Dobson, A. De Simone, Structural basis of
- 130 synaptic vesicle assembly promoted by α -synuclein. *Nat Commun* **7** (2016).
- N. J. Rutherford, B. D. Moore, T. E. Golde, B. I. Giasson, Divergent effects of the H50Q
 and G51D SNCA mutations on the aggregation of α-synuclein. *J Neurochem* 131 (2014).
- K. C. Chi, G. S. Armstrong, D. N. M. Jones, E. Z. Eisenmesser, C. W. Liu, Residue
 histidine 50 plays a key role in protecting α-Synuclein from aggregation at physiological
 pH. *Journal of Biological Chemistry* 289 (2014).
- 136 67. S. Ray, N. Singh, R. Kumar, K. Patel, S. Pandey, D. Datta, J. Mahato, R. Panigrahi, A.
- 137 Navalkar, S. Mehra, L. Gadhe, D. Chatterjee, A. S. Sawner, S. Maiti, S. Bhatia, J. A.
- 138 Gerez, A. Chowdhury, A. Kumar, R. Padinhateeri, R. Riek, G. Krishnamoorthy, S. K.
- Maji, α-Synuclein aggregation nucleates through liquid–liquid phase separation. *Nat Chem*140 **12** (2020).
- M. C. Hardenberg, T. Sinnige, S. Casford, S. T. Dada, C. Poudel, E. A. Robinson, M.
 Fuxreiter, C. F. Kaminksi, G. S. Kaminski Schierle, E. A. A. Nollen, C. M. Dobson, M.
 Vendruscolo, Observation of an α-synuclein liquid droplet state and its maturation into
 Lewy body-like assemblies. *J Mol Cell Biol* 13 (2021).
- 145 69. S. T. Dada, M. C. Hardenberg, Z. Toprakcioglu, L. K. Mrugalla, M. P. Cali, M. O.
- 146 McKeon, E. Klimont, T. C. T. Michaels, T. P. J. Knowles, M. Vendruscolo, Spontaneous

- 147 nucleation and fast aggregate-dependent proliferation of α -synuclein aggregates within
- 148 liquid condensates at neutral pH. *Proc Natl Acad Sci U S A* **120** (2023).
- Y. Wu, B. Ma, C. Liu, D. Li, G. Sui, Pathological Involvement of Protein Phase Separation
 and Aggregation in Neurodegenerative Diseases. *Int J Mol Sci* 25 (2024).
- 151 71. S. Ray, D. Chatterjee, S. Mukherjee, K. Patel, J. Mahato, Spatiotemporal solidification of
 152 α-synuclein inside the liquid droplets. *bioR* 4 (2021).
- 153 72. C. Wang, K. Zhang, B. Cai, J. E. Haller, K. E. Carnazza, J. Hu, C. Zhao, Z. Tian, X. Hu, D.
- Hall, J. Qiang, S. Hou, Z. Liu, J. Gu, Y. Zhang, K. B. Seroogy, J. Burré, Y. Fang, C. Liu,
- A. T. Brunger, D. Li, J. Diao, VAMP2 chaperones α-synuclein in synaptic vesicle co condensates. *Nat Cell Biol* 26, 1287–1295 (2024).
- 157 73. E. Jo, J. A. McLaurin, C. M. Yip, P. St. George-Hyslop, P. E. Fraser, α-Synuclein
 158 membrane interactions and lipid specificity. *Journal of Biological Chemistry* 275 (2000).
- E. R. Middleton, E. Rhoades, Effects of curvature and composition on α-synuclein binding
 to lipid vesicles. *Biophys J* 99 (2010).
- 75. C. R. Bodner, A. S. Maltsev, C. M. Dobson, A. Bax, Differential phospholipid binding of
 α-synuclein variants implicated in Parkinson's disease revealed by solution NMR
 spectroscopy. *Biochemistry* 49 (2010).
- D. L. Fortin, V. M. Nemani, S. M. Voglmaier, M. D. Anthony, T. A. Ryan, R. H. Edwards,
 Neural activity controls the synaptic accumulation of α-synuclein. *Journal of Neuroscience* 25 (2005).
- 167 77. L. A. Parra-Rivas, K. Madhivanan, B. D. Aulston, L. Wang, D. D. Prakashchand, N. P.
- Boyer, V. M. Saia-Cereda, K. Branes-Guerrero, D. P. Pizzo, P. Bagchi, V. S. Sundar, Y.
- 169 Tang, U. Das, D. A. Scott, P. Rangamani, Y. Ogawa, Subhojit Roy, Serine-129 170 phosphorylation of α -synuclein is an activity-dependent trigger for physiologic protein-171 protein interactions and synaptic function. *Neuron* **111** (2023).

172	78.	M. Al-Azzani, A. König, T. F. Outeiro, Production of Recombinant Alpha-Synuclein: Still
173		No Standardized Protocol in Sight. Biomolecules 12, 324 (2022).
174	79.	Y. Shen, A. Bax, Protein backbone and sidechain torsion angles predicted from NMR
175		chemical shifts using artificial neural networks. J Biomol NMR 56 (2013).
176	80.	J. Schindelin, I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S.
177		Preibisch, C. Rueden, S. Saalfeld, B. Schmid, JY. Tinevez, D. J. White, V. Hartenstein,
178		K. Eliceiri, P. Tomancak, A. Cardona, Fiji: an open-source platform for biological-image
179		analysis. Nat Methods 9, 676–682 (2012).
180		81. N. Ramalingam, U. Dettmer, Temperature is a key determinant of alpha- and beta-
181		synuclein membrane interactions in neurons. J Biol Chem 296, 100271 (2021).

182

183 **Figures legends**

Fig. 1. K58N mutation decreases the α-helical content affecting liposome binding. a. ¹H, ¹⁵N 184 HSQC of aSyn WT (blue) and K58N (red). Evident CSPs are labeled. b, Combined HN/N CSPs 185 generated by the K58N mutation over the aSyn sequence. Affected region is highlighted in grey. 186 c, Ha (green) and Ca (black) CSPs. d, Normalized ¹H,¹⁵N HSQC intensity ratios. Error bars are 187 calculated from signal-to-noise ratios of individual resonances. e, Secondary structure 188 calculations from NMR chemical shifts for α Syn WT (α -helix, blue; β -strand, light blue) and 189 K58N (α -helix, red; β -strand, orange). On the right a zoom of the affected region with the α -190 191 helical content is plotted. f, Micelle-bound α Syn structure (PDB ID: 1XQ8) with the positions of the different pathological mutations highlighted. g, Residue specific α -helical content over 100 ns 192 MD simulations. Error bars indicate the standard error from 40 analyzed peptides. h-i, CD 193 194 experiments of WT (h) and K58N (i) a Syn at different protein: lipid ratios. j, Ellipticity change at 222 nm upon increasing concentrations of lipids for WT (blue) and K58N (red). More negative 195 values indicate a bigger increase of α -helical structure. 196

197

198 Fig. 2. In vitro ThT-based aggregation assays for WT and K58N aSyn. (A) and (B)

Aggregation kinetic profiles of WT and K58N aSyn. Data was normalized to the maximum
fluorescence value of each run. (C) Comparison of the half-time in min to for aggregation
kinetics. (D) Comparison of maximum ThT fluorescence values of WT and K58N. Error bars
represent mean±SD.

203

Fig. 3. Characteristics of WT and K58N aSyn filaments. A) TEM micrograph of WT aSyn 204 205 amyloid filaments. Black arrows mark selected filament ends. Scale bar: 100 nm. B) TEM micrograph of K58N aSyn amyloid filaments. Black arrows indicate filament ends of exemplary 206 filaments. Scale bar: 100 nm. C) 2D class averages (706 Å box size) of twisting WT aSyn 207 filaments, illustrating the interaction between either two protofilaments (2PF) or a single 208 protofilament (1PF). Scale bar: 50 nm. D) 2D class averages (706 Å box size) reveal twisting 209 K58N aSyn filaments, again characterized by two protofilaments interacting with each other. 210 Scale bar: 50 nm. E) Overview of the electron density map of WT aSyn filaments. F) Overview of 211 the electron density map of K58N aSyn filaments. G) Amino acid sequence of human aSyn with 212 distinct regions color-coded (N-Terminus in orange, Non-amyloid component in purple, and C-213 Terminus in green). H) The electron density map together with the atomic model of WT aSyn 214 amyloid filaments featuring a single beta-sheet layer formed by two interacting protofilaments. 215 The protofilament interface is stabilized by a K45-E57 salt bridge. I) The electron density map 216 together with the atomic model of K58N aSyn amyloid filaments. The protofilament interface is 217 again stabilized by the K45-E57 salt bridge. The mutated residue is indicated in red. J) 218 219 Superposition of the WT atomic model (grey) and the K58N mutant (blue). While the doublearrow structure is similar, notable differences in the backbone highlight the impact of the K58N 220 mutation (residue marked in red) on the overall aSyn filament structure. 221

222

Fig. 4. Effect of K58N mutation on inclusion formation in cells. The pattents of inclusions formation was enivtagated using SynT/Sph1 aggregation model, which is based on the coexpression of based on the co-expression of WT or K58N SynT variants and synphilin-1. (A) Immunohistochemistry images representing the inclusion formation in H4 cells expressing WT and G14R aSyn. Scale bar: 20 μ m. (B) Quantification of the number of inclusions per cell and their area (C). For each experiment, 50 cells were counted at a 100x magnification. The data analysis was performed using a Student's t-test, and presented as mean \pm SD (*N*=3).

230

Fig. 5. aSyn K58N shows decreased condensate formation in vitro and in cells. (A) aSyn 231 phase separation in the presence of 2 mM Ca^{2+} and crowding with 15% PEG-8000, immediately 232 after PEG addition for aSyn wildtype (WT) and the disease variant aSyn K58N. aSyn 233 concentration used: 100 μ M. (B) Heatmap for turbidity measurements of aSyn phase separation in 234 the presence of 2 mM Ca²⁺. Data derived from 4 independent repeats. (C) Condensate formation 235 of aSyn WT YFP and aSyn K58N YFP upon ectopic expression with VAMP2 in HeLa cells. aSyn 236 K58N YFP does not undergo condensate formation in cells. (D) Quantification of condensate 237 formation. Data derived from incuCyte screening, 16 images per well, 3 wells per biological 238 repeat, 3 biological repeats. n indicates biological repeats. Data are represented as mean +/- SD. 239 Unpaired two-tailed t-test. 240

241

Fig. 6. Dynamic activity-dependent pS129 of K58N and WT aSyn. (A) Schematic illustration of aSyn structure exhibiting the KTKEGV repeat sequence harboring most familial PD mutations, central hydrophobic domain, and C-terminal region. The sequence alignment of aSyn is displayed below showing the conserved KTKEGV residues in yellow and sites of familial PD mutation in orange. On the right, the experimental setup is summarized. (B) A representative western blot


(WB) displaying the levels of total aSyn and pS129 from DIV17-21 rat SNCA^{-/-} rat cortical 247 neurons expressing WT and G14R aSyn, with WB quantitative analysis presented below. (C) WB 248 results of WT and G14R transduced rat SNCA^{-/-} cortical neurons that were subjected to on-plate 249 sequential extraction to isolate the cytosolic (C) and membrane (M) fractions. MJFR1 antibody 250 was used for total aSyn detection, while GAPDH and Calnexin were used as cytosolic and 251 membrane fractions controls, respectively. (D) quantitative analysis of WT and K58N aSyn 252 solubility from WB data in (C). (E) A summary of the experimental conditions to study pS129 253 dynamic reversibility, with more information are provided in the main text. (F-G) Neuronal 254 255 activity-dependent reversible phosphorylation of S129 (as outlined in schematic E) was detected in DIV17-21 rat SNCA-/- cortical neurons expressing WT or G14R, respectively, following PTX 256 stimulation (20 µM) and TTX inhibition (1 µM). WB for quantifying total aSyn and pS129 was 257 employed and panels H-L are derived from F to G. (H) The percentage of increase in pS129, 258 compared to baseline, for WT and G14R aSyn observed after 2h or 4h PTX stimulation. (I) 259 Comparison of TTX-resistant pS129 levels in WT and G14R variants relative to baseline 260 conditions (DMSO vehicle). (J) The proportion of irreversible pS129 relative to the basal (DMSO 261 vehicle) condition. (K) The proportion of irreversible pS129 relative to 2 h PTX stimulation. (L) 262 263 0.001; *P < 0.05; ns, not significant. The error bar was mean ± SD. 264


265


Fig. 7. Effect of K58N mutation on yeast cells. S. cerevisiae cells harboring WT aSyn or K58N aSyn mutation were grown to mid-log phase. (A) aSyn localization was analyzed by fluorescence microscopy. (B) Cellular viability was evaluated by spotting assay, where cultures were spotted on SD-URA agar plates.


- 270
- 271
- 272


273			
274			
275			
276			
277			
278			
279			
280			
281			
282			
283			
284			























aSyn




DAPI











С

B





E


I





F kDa 14 Dynamic reversible pS129 14



















G

K

B







D


Η

L



TTX-resistant pS129 relative to 4h stimulation





Total aSyn 2-

С

